Track market-moving stories before they get noisy

Jack Henry will accelerate the bank's fintech integration capabilities and help the bank scale for growth. This leading small business lender will be able to improve the loan financing experience for customers nationwide. Celtic Bank will utilize Jack Henry core processing along with numerous other tech solutions. , /PRNewswire/ -- Jack Henry® (Nasdaq: JKHY) announced today that Celtic Bank has selected Jack Henry to support its progressive technology strategy, allowing the bank to choose the right tools to grow its business lines while improving user experience, efficiency, and scale.

Salt Lake City-based Celtic Bank is focused on technology-enabled banking, helping businesses across all 50 states grow through financing and banking-as-a-service (BaaS) capabilities. With $5 billion in assets, the bank is consistently ranked among the nation's leading SBA lenders.

The bank selected Jack Henry's modern core processing platform, along with a suite of technology solutions. Banno Business™ will provide a modern digital banking experience for small business and commercial clients, while Enterprise Workflow will automate operational workflows and approvals, improving efficiency across the organization. Additionally, Jack Henry's open ecosystem offers the flexibility to choose from more than 1,000 third-party technology integrations.

"We were looking for more than core technology; we wanted a long-term technology strategy," said Jake Barney, Chief Financial Officer at Celtic Bank. "As our business continues to grow, we needed a technology provider that could deliver modern customer experiences, improve operational efficiency, and enable a variety of open integrations for our BaaS business. We found all these qualities in Jack Henry."

Jack Henry's strategy of delivering modern service components in the public cloud was also a key factor in Celtic Bank's decision. "We believe the core should enable innovation, not define it," Barney added. "Jack Henry's decoupled approach gives us the flexibility to choose the solutions that best fit our business, while providing a realistic path to modernization and the public cloud. It gives us the freedom to evolve our technology on our own terms as our business continues to grow."

"Celtic Bank has built an impressive business by taking a differentiated approach to business banking," said Jonathan Baltzell, President of Bank Solutions at Jack Henry. "Their strategy requires technology that's flexible enough to adapt to a diverse set of business lines while continuing to evolve with changing customer expectations. We're proud to help bring that vision to life."

About Jack Henry & Associates, Inc. ®
Jack Henry® (Nasdaq: JKHY) is a well-rounded financial technology company that strengthens connections between financial institutions and the people and businesses they serve. We are an S&P 500 company that prioritizes openness, collaboration, and user centricity – offering banks and credit unions a vibrant ecosystem of internally developed modern capabilities as well as the ability to integrate with leading fintechs. For 50 years, Jack Henry has provided technology solutions to enable clients to innovate faster, strategically differentiate, and successfully compete while serving the evolving needs of their accountholders. We empower more than 7,200 clients with people-inspired innovation, personal service, and insight-driven solutions that help reduce the barriers to financial health. Additional information is available at www.jackhenry.com. 

SOURCE Jack Henry & Associates, Inc.

Academy Sports and Outdoors, Inc. (NASDAQ:ASO) will release its second earnings report before the opening bell on Wednesday, Sept. 9.

Analysts expect the Katy, Texas-based company to report quarterly earnings of $2.08 per share, up from $1.94 per share in the year-ago period. The consensus estimate for ASO’s quarterly revenue is $1.65 billion. It reported $1.60 billion last year, according to Benzinga Pro.

On Sept. 3, Academy Sports + Outdoors announced the appointment of Matthew (Matt) M. Pasch to the role of executive vice president and chief people officer.

Academy Sports shares gained 2.9% to close at $44.94 on Friday.

Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.

Let’s have a look at how Benzinga’s most-accurate analysts have rated the company in the recent period.

Evercore ISI Group analyst Greg Melich maintained an In-Line rating and cut the price target from $60 to $55 on July 27, 2026. This analyst has an accuracy rate of 72%. Barclays analyst Adrienne Yih maintained an Equal-Weight rating and lowered the price target from $55 to $50 on June 11, 2026. This analyst has an accuracy rate of 65%. Goldman Sachs analyst Kate McShane maintained a Buy rating and cut the price target from $67 to $60 on June 10, 2026. This analyst has an accuracy rate of 69%. UBS analyst Michael Lasser maintained a Neutral rating and lowered the price target from $56 to $55 on June 10, 2026. This analyst has an accuracy rate of 78%. JP Morgan analyst Christopher Horvers maintained a Neutral rating and cut the price target from $60 to $59 on June 10, 2026. This analyst has an accuracy rate of 69%. Trending

Considering buying ASO stock? Here’s what analysts think:

Photo via Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

Experienced biotechnology executive with more than 25 years of leadership in cardiovascular and genetic medicine to lead clinical development 

Appointment strengthens executive leadership team as Editas advances EDIT-401 toward clinical development

CAMBRIDGE, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced the appointment of Dan Ory, M.D., as Chief Medical Officer, effective today.

With more than 25 years of experience spanning biotechnology leadership, cardiovascular medicine, and the development of genetic medicines, Dr. Ory will oversee the company's clinical development strategy and operations as Editas advances EDIT-401, its lead in vivo development candidate for the potential treatment of hyperlipidemia, toward the clinic, while supporting the progression of the company's broader pipeline.

Prior to joining Editas, Dr. Ory served as Chief Medical Officer at Arbor Biotechnologies, where he oversaw the global clinical trial for the company's lead in vivo gene editing program. Previously, he served as Chief Medical Officer at Casma Therapeutics, leading clinical development programs focused on rare genetic and neurodegenerative diseases. Before joining industry, Dr. Ory spent more than two decades at Washington University School of Medicine in St. Louis, where he served as the Alan A. and Edith L. Wolff Professor of Cardiology and conducted research in cholesterol metabolism and Niemann-Pick disease type C (NPC), helping advance the understanding of cholesterol homeostasis and its role in cardiovascular disease.

“Dan joins Editas at an exciting time as EDIT-401 nears clinical development for the potential treatment of hyperlipidemia, and as we continue advancing our leadership in in vivo gene editing,” said Gilmore O'Neill, M.B., M.M.Sc., President and Chief Executive Officer of Editas Medicine. “He brings deep expertise in cardiovascular medicine and the development of genetic medicines, together with a proven track record of advancing innovative therapies from scientific discovery through clinical development. His expertise in cardiovascular disease and cholesterol metabolism, combined with his experience leading clinical development for innovative genetic medicine programs, including in vivo gene editing, will strengthen our ability to execute our clinical strategy and advance our mission of developing transformative in vivo gene editing medicines for patients.”

“I am excited to join Editas as the company advances EDIT-401 toward the clinic,” said Dr. Ory. “The opportunity to apply in vivo gene editing to cardiovascular disease, an area where significant unmet need remains, represents an exciting new frontier in medicine. EDIT-401 has the potential to redefine the treatment paradigm as a best-in-class therapeutic for hyperlipidemia through a one-time gene editing approach, and I have been impressed by the strength of the science and the talented team behind it. I look forward to working alongside my colleagues to advance EDIT-401 into the clinic, progress the broader pipeline, and work to ultimately deliver transformative medicines for patients living with serious diseases.”

About Dan Ory, M.D.
Dr. Ory, M.D., is an accomplished biotechnology executive with more than 25 years of leadership in cardiovascular and genetic medicine.

Most recently, Dr. Ory served as Chief Medical Officer at Arbor Biotechnologies, where he led the company's clinical development strategy and advancement of its next-generation gene editing pipeline. Previously, he served as Chief Medical Officer at Casma Therapeutics, where he oversaw clinical development programs focused on rare genetic and neurodegenerative diseases.

Before transitioning to industry, Dr. Ory was the Alan A. and Edith L. Wolff Professor of Cardiology at Washington University School of Medicine in St. Louis, where his laboratory made significant contributions to the understanding of cholesterol metabolism and advanced the field of Niemann-Pick disease type C (NPC), a rare neurodegenerative cholesterol storage disorder. He also led multiple clinical trials in NPC disease and was scientific co-founder of Vtesse Therapeutics, a rare disease company. Clinically, Dr. Ory’s practice was focused on preventive and diagnostic cardiology, specializing in cardiovascular risk assessment and the application of stress echocardiography and nuclear perfusion imaging to guide the evaluation and management of patients at risk for coronary artery disease.

During his academic career, he authored more than 160 peer-reviewed publications and is an inventor on numerous patents related to cardiovascular and rare disease research. He was elected a Fellow of the American Association for the Advancement of Science (AAAS) and is a member of both the American Society for Clinical Investigation (ASCI) and the Association of American Physicians (AAP).

Dr. Ory received an A.B. from Harvard College and an M.D. from Harvard Medical School. He completed postdoctoral training at the Whitehead Institute at MIT, an internal medicine residency at Brigham and Women's Hospital, and a fellowship in cardiology at Massachusetts General Hospital.

About Editas Medicine 
As a pioneering gene editing company, Editas Medicine is focused on translating the power and potential of CRISPR genome editing systems into a robust pipeline of transformative in vivo medicines for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize durable, precision in vivo gene editing medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute’s Cas12a patent estate and Broad Institute and Harvard University’s Cas9 patent estates for human medicines. For the latest information and scientific presentations, please visit www.editasmedicine.com.

Forward-Looking Statements
This press release contains forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995. The words ‘‘anticipate,’’ ‘‘believe,’’ ‘‘continue,’’ ‘‘could,’’ ‘‘estimate,’’ ‘‘expect,’’ ‘‘intend,’’ ‘‘may,’’ ‘‘plan,’’ ‘‘potential,’’ ‘‘predict,’’ ‘‘project,’’ ‘‘target,’’ ‘‘should,’’ ‘‘would,’’ and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: uncertainties inherent in the initiation, timing, progress, and results of preclinical studies and clinical trials; uncertainty regarding availability and timing of results from preclinical studies and clinical trials; uncertainties relating to planned regulatory submissions to initiate clinical trials, including that results of preclinical studies will warrant such submissions or that regulatory agencies may require additional preclinical studies, that regulatory submissions shall occur on the expected timelines and that regulatory authorities will provide clearance for trials to be initiated on the expected timelines or at all; and uncertainties as to whether the Company’s cash resources are sufficient to fund its foreseeable and unforeseeable operating expenses and capital expenditure requirements for the period anticipated. These and other risks are described in greater detail under the caption “Risk Factors” included in the Company’s most recent Annual Report on Form 10-K, which is on file with the Securities and Exchange Commission, as updated by the Company’s subsequent filings with the Securities and Exchange Commission, and in other filings that the Company may make with the Securities and Exchange Commission in the future. Any forward-looking statements contained in this press release represent the Company’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law, the Company explicitly disclaims any obligation to update any forward-looking statements.

Investor and Media Contacts:

[email protected]
[email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/26e428aa-c407-46ad-8497-f6436c805022

Dan Ory, M.D. Editas Medicine today announced the appointment of Dan Ory, M.D., as Chief Medical Officer, effectiv...

ACCG-2671 (oral small molecule amylin receptor agonist) demonstrated a ~6-day half-life, no serious adverse events, and evidence of target engagement including up to 3.3% body weight loss in Phase 1/2a SAD clinical trial

First participants dosed with ACCG-2671 in the 12-week MAD portion of the Phase 1/2a clinical trial; topline data expected in 1H 2027

Aleniglipron (oral small molecule selective GLP-1 receptor agonist) demonstrated up to 16.2% mean reduction in body weight at 72 weeks with no observed plateau, and improved tolerability with a 2.5 mg starting dose, including less than 5% study-drug discontinuation rates due to adverse events in the ACCESS OLE clinical trial

ACCOMPLISH-1 and ACCOMPLISH-2 registrational Phase 3 clinical trials for aleniglipron enrollment ongoing; topline data expected in 2H 2028

Company to host conference call today at 8:30 a.m. ET

SAN FRANCISCO, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on chronic weight management, today reported positive clinical trial results from its two lead product candidates: ACCG-2671, an oral, non-peptide, small molecule dual amylin and calcitonin receptor agonist (DACRA), and aleniglipron, an oral, non-peptide, small molecule glucagon-like peptide-1 (GLP-1) receptor agonist.

Structure announced positive topline data for ACCG-2671 in a Phase 1/2a single ascending dose (SAD) trial in healthy participants without obesity. In the SAD trial, ACCG-2671 demonstrated a long half-life of approximately 6 days supporting potential once-weekly dosing, with no serious adverse events (SAEs) or events of liver enzyme elevations. Exploratory findings showed pharmacodynamic (PD) activity and evidence of target engagement, including a 3.3% mean reduction in body weight following a single dose, as well as an encouraging decrease in CTX-1, a biomarker of bone resorption relevant to bone health. Based on these encouraging findings, the Company has initiated the multiple ascending dose (MAD) portion of the Phase 1/2a clinical trial with topline data expected in the first half of 2027.

Structure also reported positive 72-week results for aleniglipron in the ACCESS open-label extension (OLE) clinical trial. Participants receiving the 180 mg dose of aleniglipron achieved up to 16.2% body weight loss at 72 weeks, with no evidence of a plateau in weight loss. Compared with ACCESS participants who previously initiated dosing with a 5 mg starting dose, placebo participants who crossed over to aleniglipron in the OLE started with a lower 2.5 mg dose and demonstrated improved tolerability. Across all dose groups, fewer than 5% of participants discontinued treatment due to adverse events, and no off-target safety signals were observed. These results reinforce aleniglipron’s previously observed clinical profile, with consistent, potentially best-in-class weight loss and favorable tolerability, further supporting the ongoing Phase 3 ACCOMPLISH program which initiated in August 2026.

“ACCG-2671 represents the first reported clinical data for an oral small molecule amylin receptor agonist, and we believe its initial observed clinical profile is quite unique,” said Raymond Stevens, Ph.D., Chief Executive Officer of Structure Therapeutics. “In addition, the 72-week OLE results demonstrate aleniglipron’s exceptional consistency and potential for a best-in-class oral small molecule weight loss profile, particularly when considering a short exposure period at the top dose in our dose range finding study. The Phase 3 clinical trial now underway puts Structure in a very strong position to be highly competitive. There remains a clear need for oral therapies that have the potential to combine greater convenience with scalable and cost-effective manufacturing, broaden access and choices for the large and diverse worldwide population living with obesity.”

Blai Coll, M.D., Ph.D., Chief Medical Officer of Structure Therapeutics, added, “The early results of ACCG-2671 represent an innovative step in targeting the amylin mechanism. In the SAD clinical trial, ACCG-2671 exceeded our expectations with its significant potency along with a prolonged half-life enabling the potential for once weekly dosing. The 3.3% body weight reduction and bone health biomarker changes after a single dose are also very encouraging signs of target engagement, and we are excited to be enrolling our 12-week MAD clinical trial of ACCG-2671 in participants living with obesity.”

Dr. Coll continued, “We are equally encouraged by the OLE results, which reinforce aleniglipron’s consistent and potentially class-leading weight loss profile. Participants achieved up to 16.2% body weight loss at 72 weeks with no evidence of weight loss plateau, and fewer than 5% discontinued treatment due to adverse events. Together, these results demonstrate exciting momentum across two complementary oral small molecule programs with the potential to meaningfully expand treatment options for chronic weight management.”

ACCG-2671 (Oral Small Molecule DACRA): Phase 1 SAD Topline Clinical Trial Results

The SAD portion of the Phase 1/2a clinical trial evaluated the safety, tolerability, pharmacokinetics (PK) and exploratory PD effects of ACCG-2671 in 31 healthy adult participants without obesity. A wide range of doses were explored in this first-in-human study to inform the appropriate starting dose and titration regimen for the MAD study. Participants received a single dose of 1, 2, 5, or 10 mg of ACCG-2671 or placebo.

ACCG-2671 demonstrated a favorable plasma PK profile showing rapid absorption with Tmax at 1 – 1.5 hours. Exposure was consistent with dose proportionality, and the terminal half-life was approximately 6 days supporting further evaluation of daily and weekly dosing.

ACCG-2671 was generally well tolerated with a favorable safety profile. There were no SAEs, no drug related treatment-emergent adverse events (TEAEs) leading to treatment discontinuation, and no events of drug-induced liver injury. No nausea or vomiting was reported in the placebo, 1 mg or 2 mg dose cohorts. Dose-related gastrointestinal events emerged at 5mg, with nausea (4/5 participants) and vomiting (3/5 participants), and at 10 mg (6/6 participants). These findings informed the starting doses and gradual titration strategies currently being evaluated in the ongoing MAD clinical trial.

Exploratory findings with a single dose of ACCG-2671 indicated encouraging and early PD activity. A single 10 mg dose (n=6) was associated with mean body weight reductions of 3.3% at Day 24. CTX-1, a well-recognized biomarker of bone resorption, decreased by approximately 60% on Day 2 across the active dose cohorts. Together, these findings provide evidence of target engagement and support further evaluation of ACCG-2671 as a potential monotherapy as well as part of combination regimens.

Structure has begun dosing in the MAD portion of the ongoing Phase 1/2a study of ACCG-2671. The randomized, placebo-controlled MAD portion will evaluate the safety, tolerability and PK of multiple ascending oral doses of ACCG-2671 administered for 84 days across five cohorts of participants living with obesity. The clinical trial will evaluate different doses and titration regimens, dosing frequencies, with daily and weekly dosing regimens, and includes a cohort of participants receiving a stable dose of an injectable GLP-1 receptor agonist, providing an initial assessment of ACCG-2671 when administered in combination with a GLP-1 receptor agonist. The encouraging SAD results observed to date, together with the data from the ongoing MAD clinical trial, could further establish ACCG-2671’s potential as a differentiated and valuable treatment option, both as monotherapy and combination therapy with GLP-1 receptor agonists. Topline data for the MAD portion of the Phase 1/2a clinical trial are expected in the first half of 2027.

Aleniglipron (Oral Small Molecule Selective GLP-1 Receptor Agonist): ACCESS OLE Results

The ACCESS OLE clinical trial is a prespecified 36-week extension of the Phase 2b ACCESS clinical trial (NCT06693843) designed to evaluate the longer-term safety and tolerability of aleniglipron and the durability of weight loss through 72 weeks of treatment. 87% of eligible participants who completed the initial 36-week double-blind treatment period in ACCESS entered the OLE. Participants continued once-daily treatment in the OLE trial, with doses titrated every four weeks, while participants originally assigned to placebo crossed over to aleniglipron at Week 36 starting with a lower 2.5 mg dose. The OLE also evaluated whether the lower starting dose improved gastrointestinal tolerability. Since participants were titrated to the highest dose of 180 mg after Week 60, this resulted in relatively limited exposure to the 180 mg dose by Week 72.

Most participants enrolled in the OLE portion of the study completed the 72 weeks on treatment. Building on previously reported interim results from the ACCESS OLE at 56 weeks in March 2026, aleniglipron demonstrated continued weight reduction at 72 weeks. Participants originally randomized to the 45 mg, 90 mg and 120 mg arms in the ACCESS trial who continued into the OLE and dosed up to 180 mg, achieved weight loss of 11.6%, 14.4% and 16.2%, respectively, with no evidence of weight loss plateau in the two top doses. More than one-third of participants in the highest dose cohorts, 90 mg and 120 mg, achieved more than 20% body weight reduction, with mean absolute body weight loss of 35.9 and 40.5 pounds, respectively.

Participants, who were originally assigned to placebo in the ACCESS clinical trial and crossed over into the OLE at week 36, started with a 2.5 mg dose of aleniglipron, titrated every four weeks and achieved weight loss of 9.0%, or 22.7 pounds, after 36 weeks of treatment.

Aleniglipron’s safety and tolerability profile remained consistent through 72 weeks. Treatment discontinuations due to TEAEs occurred in fewer than 5% of participants in the OLE. Placebo participants who crossed over into the OLE with a 2.5 mg starting dose and were gradually up-titrated every four weeks to 180 mg demonstrated improved gastrointestinal tolerability compared with the 5 mg starting dose in the double-blind portion of ACCESS.

There were no cases of drug-induced liver injury and all observed liver-enzyme elevations resolved without treatment discontinuation consistent with prior aleniglipron clinical trials.

The efficacy seen in the 72-week OLE trial, especially given that participants were titrated to the highest 180 mg dose at approximately Week 60 and most dose groups had not yet reached an efficacy plateau, demonstrated aleniglipron’s durable, clinically meaningful and competitive weight reduction and a consistent and promising long-term safety and tolerability profile, reinforcing its potential as a differentiated once-daily oral GLP-1 receptor agonist for chronic weight management.

Aleniglipron is currently being evaluated in the ongoing Phase 3 ACCOMPLISH program, comprising two randomized, double-blind, placebo-controlled clinical trials. ACCOMPLISH-1 (NCT07654361) is enrolling up to 3,600 adults living with obesity or overweight with at least one weight-related comorbidity, while ACCOMPLISH-2 (NCT07654374) is enrolling up to 1,100 adults living with obesity or overweight and type 2 diabetes mellitus (T2DM). In both trials, participants will receive placebo or one of three aleniglipron maintenance doses, 45 mg, 90 mg or 180 mg, following a 2.5 mg starting dose and dose escalation at four-week intervals. The program is designed to evaluate the long-term efficacy and safety of aleniglipron and support global regulatory marketing applications for chronic weight management. We expect topline data in the second half of 2028.

Upcoming Milestones in Q4 2026

Additional clinical data expected in the fourth quarter of 2026 could further define aleniglipron’s differentiated clinical profile in terms of the quality of weight loss, treatment of patients with T2DM and the transition from approved injectable incretin medicines. Expected data readouts include:

Phase 2 Body Composition clinical trial (NCT07169942): Results from a 44-week study evaluating aleniglipron’s effects on body fat and overall body composition.Phase 2 T2DM clinical trial (NCT07400588): Results in adults living with T2DM and obesity or overweight.Phase 1 SWITCH clinical trial: Results evaluating the transition from approved injectable GLP-1 medicine to once-daily oral aleniglipron. Conference Call and Webcast Information
Structure Therapeutics will host a conference call and webcast today, September 8, 2026 at 8:30 a.m. Eastern Time. A live webcast of the call will be available on the Investor Relations page of Structure Therapeutics’ website at https://ir.structuretx.com/events-presentations/events.

The webcast can also be accessed directly HERE.

To access the call by phone, participants should visit this link HERE to receive dial-in details.

The webcast will be made available for replay on Structure Therapeutics’ website beginning approximately two hours after the live event. The replay of the webcast will be available for at least 90 days.

About ACCG-2671
ACCG-2671 is an investigational, oral small molecule dual amylin and calcitonin receptor agonist being developed as a potential first-in-class oral amylin therapy for obesity and related metabolic diseases. Amylin is a clinically validated metabolic hormone that plays an important role in regulating appetite, food intake and body weight. Discovered through Structure Therapeutics’ structure-based drug discovery platform, ACCG-2671 is being evaluated in a Phase 1b/2a clinical program. Its oral small molecule profile could support development both as a monotherapy and as a potential combination backbone with GLP-1 receptor agonists and other metabolic therapies.

About Aleniglipron
Aleniglipron (GSBR-1290) is an investigational, once-daily, orally available small molecule agonist of the glucagon-like peptide-1 (GLP-1) receptor, a clinically validated target for the treatment of obesity and type 2 diabetes mellitus. Discovered through Structure Therapeutics’ structure-based drug discovery platform, aleniglipron was designed as a biased G protein-coupled receptor agonist that selectively activates the G-protein signaling pathway.

About Structure Therapeutics
Structure Therapeutics is a science-driven clinical-stage biopharmaceutical company focused on discovering and developing innovative oral small molecule treatments for chronic metabolic conditions with significant unmet medical needs. Utilizing its next generation structure-based drug discovery platform, the Company has established a robust GPCR-targeted pipeline, featuring multiple wholly-owned proprietary clinical-stage oral small molecule compounds designed to surpass the scalability limitations of traditional biologic and peptide therapies and be accessible to more people living with obesity around the world. For additional information, please visit www.structuretx.com.

Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including, without limitation, statements concerning: the Company’s future plans and prospects; any expectations regarding the potential benefits, tolerability and safety profile, accessibility, scalability, combinability, capability, efficacy, convenience, expected effects and future application of aleniglipron, ACCG-2671 and any other of the Company’s investigational compounds; any presumption that topline, interim or preliminary data will be representative of final data or data in later clinical trials; the belief that aleniglipron represents a potentially best-in-class small molecule GLP-1 agonist and has the potential to become a differentiated once-daily oral GLP-1 receptor agonist for chronic weight management; the belief that data to date from the Company’s trials support the ongoing Phase 3 ACCOMPLISH program; the belief that the Company is in a very strong position to be highly competitive; the belief that oral small molecules have the potential to combine convenient administration with scalable manufacturing; the belief that the Company’s oral amylin and GLP-1 programs have the potential to meaningfully expand treatment options for people living with obesity; the belief that ACCG-2671 represents a potentially first-in-class small molecule amylin agonist and its potential development as a monotherapy and as a complementary combination backbone with GLP-1 receptor agonists; and the expected timing of data results from the Phase 1/2a ACCG-2671 MAD trial, Phase 3 aleniglipron trials and other ongoing clinical trials. In addition, when or if used in this press release, the words and phrases “anticipated,” “believe,” “expect,” “may,” “on track,” “plan,” “potential,” “suggests,” “to be,” “to begin,” “will,” and similar expressions and their variants, as they relate to the Company may identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Although the Company believes the expectations reflected in such forward-looking statements are reasonable, the Company can give no assurance that such expectations will prove to be correct. Readers are cautioned that actual results, levels of activity, safety, performance or events and circumstances could differ materially from those expressed or implied in the Company’s forward-looking statements due to a variety of risks and uncertainties, which include, without limitation: risks and uncertainties related to topline results that the Company reports are based on preliminary analysis of key efficacy and safety data, and such data may change following a more comprehensive review of the data related to the clinical trial and such topline data may not accurately reflect the complete results of a clinical trial; the preliminary nature of the results due to the length of the study and sample size and the results from earlier clinical studies not necessarily being predictive of future results; potential delays in the commencement, enrollment and completion of the Company’s Phase 3 clinical program and other clinical studies; the Company’s ability to advance aleniglipron, ACCG-2671, ACCG-3535, LTSE-2578, and its other therapeutic candidates, obtain regulatory approval of, and ultimately commercialize the Company’s therapeutic candidates; competitive products or approaches limiting the commercial value of the Company’s product candidates; the Company’s ability to fund development activities and achieve development goals; and other risks and uncertainties described in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s latest Quarterly Report on Form 10-Q and future reports the Company may file with the SEC from time to time. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

Investors:
Corey Davis, Ph.D.
LifeSci Advisors, LLC
212-915-2577
[email protected]

Jennifer Robinson
Structure Therapeutics Inc.
[email protected]

Media:
Dan Budwick
1AB
[email protected]

 | Source: Intellia Therapeutics, Inc.

FDA sets Prescription Drug User Fee Act (PDUFA) date of March 10, 2027Positions lonvo-z to be the world’s first in vivo CRISPR-based therapy and the only one-time HAE treatment, if approved CAMBRIDGE, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for lonvo-z and granted the BLA Priority Review with a PDUFA target action date of March 10, 2027. Additionally, FDA has advised the company that it is not currently planning to hold an advisory committee to discuss the application. If approved, lonvo-z would be the world’s first in vivo CRISPR-based therapy and the only one-time treatment for HAE.

“Today marks an important milestone for the patients we are committed to serving and for Intellia’s pioneering work in the field of in vivo gene editing,” said John Leonard, M.D., Intellia President and Chief Executive Officer. “Backed by compelling Phase 3 data, we believe lonvo-z could fundamentally change the way HAE is treated and are excited by its potential to become the world's first approved in vivo CRISPR-based therapy. With the FDA’s Priority Review underway, our team is well prepared to deliver this one-time treatment to patients who are waiting for new options.”

Joshua Jacobs, M.D., Medical Director, Allergy and Asthma Clinical Research, Inc., and a HAELO trial investigator, added, “HAE is an unpredictable disease that can be responsible for profound disability and place patients at risk for fatal attacks. Today’s announcement is exciting because it advances us one step closer to potentially having a one-time treatment option available for patients who continue to be burdened by this chronic disease.”

The BLA is supported by positive data from Intellia’s global Phase 3 HAELO clinical trial, which was fully enrolled with 80 patients in just nine months and was designed to evaluate the efficacy and safety of a one-time 50 milligram dose of lonvo-z in adults and adolescents aged 16 years and older with Type 1 or Type 2 HAE. HAELO met its primary and all key secondary endpoints, demonstrating an 87% reduction (p<0.0001) in mean monthly attacks for lonvo-z compared with placebo during the efficacy evaluation period (weeks 5 to 28). In addition, 62% of patients in the lonvo-z arm were entirely attack free and HAE therapy free for the six-month efficacy evaluation period, compared with 11% of patients in the placebo arm (p<0.0001). As of the February 10, 2026 data cutoff, all patients who received lonvo-z at baseline or in crossover after week 28 remained free from long-term prophylaxis therapy.

Favorable safety and tolerability data were observed for lonvo-z as of the data cutoff. The most common treatment emergent adverse events during the primary observation period (infusion through week 28) that were higher in the lonvo-z group compared to placebo were infusion-related reactions, headache, fatigue, back pain, and upper respiratory tract infection. All reported treatment emergent adverse events were mild or moderate and there were no serious adverse events observed in the lonvo-z arm.

About Lonvo-z
Based on Nobel Prize-winning CRISPR/Cas9 technology, lonvo-z has the potential to become the first one-time treatment for hereditary angioedema (HAE). Lonvo-z is an in vivo CRISPR gene editing candidate that is intended to permanently lower kallikrein by inactivating the kallikrein B1 (KLKB1) gene with a single dose that is administered in an outpatient setting. Lonvo-z has received five notable regulatory designations: Orphan Drug and Regenerative Medicine Advanced Therapy (RMAT) Designations by the U.S. Food and Drug Administration (FDA), the Innovation Passport by the U.K. Medicines and Healthcare products Regulatory Agency (MHRA), Priority Medicines (PRIME) Designation by the European Medicines Agency, as well as Orphan Drug Designation (ODD) by the European Commission.

About Hereditary Angioedema
HAE is a rare, genetic disease characterized by severe, recurring and unpredictable inflammatory attacks in various organs and tissues of the body, which can be painful, debilitating and life-threatening. It is estimated that one in 50,000 people are affected by HAE. There are preventative and on-demand treatment options to help manage the condition, including long- and short-term prophylaxis used to prevent swelling attacks. Current treatment options often include lifelong therapies, which may require chronic intravenous (IV) or subcutaneous (SC) administration as often as twice per week or daily oral administration to ensure constant pathway suppression for disease control. Despite chronic administration, breakthrough attacks may still occur. Kallikrein inhibition is a clinically validated strategy for the preventive treatment of HAE attacks.

About Intellia Therapeutics

Intellia Therapeutics, Inc. (Nasdaq: NTLA) is a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies. The company’s mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments. With deep scientific, technical and clinical development experience, Intellia aims to reset the standard for medicine by durably treating the root causes of disease. Learn more at intelliatx.com and follow us @intelliatx.

Forward-Looking Statements

This press release contains “forward-looking statements” of Intellia Therapeutics, Inc. (“Intellia” or the “Company”) within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements regarding Intellia’s beliefs and expectations concerning: the success and advancement of its program for lonvoguran ziclumeran or “lonvo-z” (formerly known as NTLA-2002) for the treatment of hereditary angioedema (“HAE”), including its expectations regarding review and approval of its biologics license application (“BLA”) for lonvo-z, such as whether the FDA will hold an advisory committee to discuss the BLA and the timing of such review and approval based on the Prescription Drug User Fee Act ("PDUFA") target action date of March 10, 2027 for the BLA; its belief that lonvo-z could fundamentally change the way HAE is treated and has the potential to become the world's first approved in vivo CRISPR-based therapy; and its expectations regarding its preparations for and the potential success of the commercial launch of lonvo-z, if approved.

Any forward-looking statements in this press release are based on management’s current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: uncertainties related to the conduct of clinical studies and other development and commercialization requirements for its product candidates, including lonvo-z, including risks related to the review and approval of the BLA for lonvo-z and the ability to develop and successfully commercialize lonvo-z or any of Intellia’s product candidates; risks related to Intellia’s ability to protect and maintain its intellectual property position; risks related to Intellia’s relationship with third parties, including its contract manufacturers, collaborators, licensors and licensees; risks related to the ability of its licensors to protect and maintain their intellectual property position; risks related to the results of preclinical studies or clinical studies not being predictive of future results in connection with future studies; the risk that clinical study results will not be positive; and risks related to the potential delay of planned clinical trials due to regulatory feedback or other developments. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Intellia’s actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in Intellia’s most recent annual report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in Intellia’s other filings with the Securities and Exchange Commission, including its recent quarterly report on Form 10-Q. All information in this press release is as of the date of the release, and Intellia undertakes no duty to update this information unless required by law.

Investor Contact:
Jason Fredette
Vice President, Investor Relations and Corporate Communications
Intellia Therapeutics, Inc.
[email protected]

Media Contact:
Mike Tattory
Vice President
LifeSci Communications
[email protected] 

BERKELEY, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Rigetti Computing, Inc. (Nasdaq: RGTI) (“Rigetti” or the “Company”), a pioneer in full-stack quantum-classical computing, today announced that its wholly owned subsidiary, Rigetti & Co, LLC, has signed a definitive agreement with the U.S. Department of Commerce (the “Department”) for an award of $100 million in funding to accelerate superconducting quantum computing R&D.

The funding is allocated under the CHIPS Research and Development Office Broad Agency Announcement pursuant to the CHIPS Act.

Under this definitive agreement, Rigetti will pursue three R&D projects that aim to address major technical bottlenecks in scaling superconducting quantum computing and will accelerate the Company’s roadmap towards utility-scale quantum computing:

Compressing readout electronics into an integrated, miniaturized packageExpanding cryogenic capacity by orders of magnitude using a new cryostat architectureDeveloping the fabrication capabilities for high-connectivity chip architectures
Quantum computing has tremendous promise to dramatically transform critical areas including cryptography, chemistry, materials science, mathematical optimization, and AI/machine learning. Governments worldwide are investing in this emerging technology given the national security and economic implications of quantum advantage.

“We are proud to be selected by the U.S. government to accelerate R&D and progress against our roadmap to deliver commercially viable quantum computing capabilities,” says Dr. Subodh Kulkarni, Rigetti CEO. “Solving crucial challenges in scaling gives us the opportunity to transform the industry by putting large-scale quantum computers in the hands of America’s quantum computing researchers faster. Shortening the time to build quantum systems at scale and reducing their cost will also allow for broader adoption, which will strengthen our domestic quantum computing ecosystem.”

The Department will receive a minority, non-controlling equity stake in Rigetti as a condition for receiving the funds to enhance the return for the U.S. taxpayer.

About Rigetti
Rigetti is a pioneer in full-stack quantum computing. Rigetti quantum computers are based on superconducting qubits, which are widely believed to be the leading qubit modality given their maturity, clear path to scaling, and fast gate speeds. Rigetti quantum computing systems achieve gate speeds of 50-70 nanoseconds, which is about 10,000 times faster than trapped-ion systems and 100 times faster than neutral-atom systems.

Rigetti sells on-premises 9-qubit to 108-qubit quantum computing systems, which support national laboratories and quantum computing centers. Rigetti’s Cepheus 36-qubit to 108-qubit systems are based on the Company’s proprietary chiplet-based technology and include the Company’s control electronics. Rigetti’s 9-qubit Novera QPU supports a broader R&D community with a high-performance, on-premises QPU designed to plug into a customer’s existing cryogenic and control systems.

The Company operates quantum computers over the cloud through its Rigetti Quantum Cloud Services (QCS) platform, enabling global enterprise, government, and research clients to pursue R&D. The Company’s proprietary quantum-classical infrastructure provides high-performance integration with public and private clouds for practical quantum computing.

Rigetti developed the industry’s first multi-chip quantum processor for scalable quantum computing systems. Leveraging this proprietary technology, Rigetti deployed the industry’s largest multi-chip quantum computer in 2026 with Cepheus-1-108Q, based on twelve 9-qubit chiplets tiled together. The Company designs and manufactures its chips in-house at Fab-1, the industry’s first dedicated and integrated quantum device manufacturing facility. Learn more at https://www.rigetti.com/.

Rigetti Media Contact
[email protected]

Cautionary Language and Forward-Looking Statements

Certain statements in this communication may be considered “forward-looking statements” within the meaning of the federal securities laws, including with respect to the Company’s expectations regarding its future success and performance including expectations with respect to its R&D; achieving the aim of the three R&D projects being pursued under the definitive agreement; the promise quantum computers have to dramatically transform critical areas including cryptography, chemistry, materials science, mathematical optimization, and AI/machine learning; the timeline for building quantum systems at scale and reducing their costs; and the Company’s ability to receive funding amounts as contemplated by the definitive agreement, including the timeline for such funding. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by the Company and its management, are inherently uncertain. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: the Company’s issuance of securities to the Department pursuant to the definitive agreement (including dilution to existing stockholders); the Company’s ability to achieve milestones, technological advancements, including with respect to its technology roadmap; Company’s ability to deliver products to customers in time or at all, including actions by customers, such as controls over their facilities and cancelling orders; the ability of the Company to obtain government contracts successfully and in a timely manner and the availability of government funding; the potential of quantum computing; the success of the Company’s partnerships and collaborations; the Company’s ability to accelerate its development of multiple generations of quantum processors; the outcome of any legal proceedings that may be instituted against the Company or others; the ability to maintain relationships with customers and suppliers and attract and retain management and key employees; costs related to operating as a public company; changes in applicable laws or regulations; the possibility that the Company may be adversely affected by other economic, business, or competitive factors; the Company’s estimates of expenses and profitability; the evolution of the markets in which the Company competes; the ability of the Company to implement its strategic initiatives and expansion plans; the expected use of proceeds from the Company’s past and future financings or other capital; the sufficiency of the Company’s cash resources; unfavorable conditions in the Company’s industry, the global economy or global supply chain, including rising inflation and interest rates, deteriorating international trade relations, political turmoil, natural catastrophes, military conflicts, and terrorist attacks; and other risks and uncertainties set forth in the section entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 and Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 and other documents filed by the Company from time to time with the Securities and Exchange Commission. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and the Company assumes no obligation and does not intend to update or revise these forward-looking statements other than as required by applicable law. The Company does not give any assurance that it will achieve its expectations.

A top Wall Street analyst is standing behind a bold price target on IREN while the stock sits deep in the red, and the gap between where shares trade today and where the bulls say they belong tells a story…

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

IREN (NASDAQ:IREN) trades at $44.68. The Wall Street consensus target sits at $77.84, implying roughly 74% upside. Bernstein’s Gautam Chhugani, meanwhile, carries a Street-high $100 price target, a call that would essentially double the stock from here.

IREN is a former Bitcoin miner rapidly rebuilding itself as an AI cloud and GPU data center operator, with liquid-cooled NVIDIA GB300 clusters going into sites across Texas, Oklahoma, British Columbia, Spain, and Australia. Wall Street cares because IREN has landed anchor contracts with Microsoft and NVIDIA that few peers can match. The gap between price and target matters because a stock this heavily contracted usually does not trade this far below Street models unless something has spooked the market.

Impairments and a Revenue Miss Slammed the Stock The most recent leg lower came with Q4 FY26 earnings. IREN reported revenue of $137.2 million, missing consensus by 2.52% and down 26.8% year over year as the company deliberately wound down its legacy mining business. The bigger shock was a GAAP net loss of $684.0 million, driven by a $450.4 million non-cash impairment on decommissioned mining hardware.

The selloff was violent. IREN touched a 52-week high of $76.87 earlier in the cycle before collapsing to a 52-week low of $27.05, a peak-to-trough drawdown well above 60%. Even after a sharp bounce, shares still sit roughly 42% below that high. Adjusted EBITDA fell to $19.2 million from $59.5 million the prior quarter, and near-term EPS estimates keep drifting lower, with the quarter ending September 2026 now pegged at negative $0.51 versus negative $0.26 thirty days ago.

Why the Bulls Are Doubling Down Instead of Downgrading Bernstein’s Chhugani, one of the top-ranked digital assets analysts on the Street, is modeling IREN as an AI Cloud Infrastructure and Neocloud Hyperscaler rather than a Bitcoin miner. That reframing is central to the bull case, and it puts IREN alongside the picks-and-shovels names powering the AI buildout (we profiled seven of them, from power to cooling, in a free report you can grab here). The contracts backing it are real: a $9.7 billion multi-year Microsoft deal, a $3.4 billion five-year NVIDIA AI Cloud contract with up to $2.1 billion in NVIDIA equity investment that vests as GPU deployments scale, plus a newly disclosed frontier AI lab contract.

Analysts point to specific milestones. Management says 2026 capacity is largely sold out, with $4 billion of contracted ARR targeted by year-end 2026 versus $1 billion operating currently. Recent three-year contracts are priced at more than $20 million per megawatt, with active discussions at $25 million per megawatt. IREN has also secured roughly $19 billion in funding over the preceding 12 months, quieting a major bear talking point.

Coverage skews decisively bullish. Of the analysts tracked, 1 rates it Strong Buy, 12 Buy, 3 Hold, 0 Sell, and 1 Strong Sell. Recent activity has been dominated by target increases rather than cuts, and Bernstein’s $100 sits at the top of that stack.

Neocloud Peers Are Sitting in the Same Discount Bin The entire neocloud group sold off together, and every major name still trades well below Wall Street’s target. IREN fits squarely inside that trend.

Cipher Mining (NASDAQ:CIFR) trades at $17.74 against a $32.18 target, roughly 81% implied upside. Coverage is unusually clean, with 5 Strong Buy and 12 Buy ratings and zero Holds or Sells. Recent revisions have skewed higher on AWS and Fluidstack lease progress.

TeraWulf (NASDAQ:WULF) sits at $16.51 versus a $36.34 target, an eye-catching 120% implied upside anchored by its 20-year Anthropic lease. Ratings are all bullish: 5 Strong Buy, 13 Buy, with recent revisions trending up.

Core Scientific (NASDAQ:CORZ) changes hands at $17.89 versus a $37.12 target, roughly 107% upside, backed by a 15-year AMD partnership and CoreWeave anchor tenancy. Analyst posture is 3 Strong Buy, 13 Buy, 1 Hold.

TeraWulf carries the largest implied upside in the group. IREN sits behind WULF and CORZ on that metric, but Bernstein’s $100 call, if realized, would leapfrog every peer.

Rating Mix Skews Buy, Performance Beats the Index IREN currently trades at $44.68 with a consensus target of $77.84 from 17 covering analysts, implying about 74% upside on the average and about 124% to Bernstein’s Street-high. Shares are up 18.29% year to date, ahead of the S&P 500’s 12.94%, and up 70.99% over the past year.

The near term has been rougher and then sharply better. IREN is up 26.04% over the past week and 14.89% over the past month, a bounce off the mid-August lows. Ratings shake out as follows:

Strong Buy: 1 Buy: 12 Hold: 3 Sell: 0 Strong Sell: 1 Targets are one data point among many, and the imbalance here is stark.

The Bull Case Hinges on Execution, the Bear Case on Capex The bull case holds if management can convert its $4 billion contracted ARR target and sold-out 2026 capacity into actual reported revenue in the March quarter and beyond. Horizon 1 has already been delivered to Microsoft, Horizons 2 through 4 are in flight, and financing is largely locked. If pricing per megawatt holds near $25 million and NVIDIA’s equity investment keeps vesting, Bernstein’s $100 call is defensible.

The bear case builds if the capex load starts wobbling. FY27 capex guidance of $25 to $30 billion is enormous, financing markets could tighten, and IREN still has to demonstrate flawless execution across Texas, Spain, and Australia simultaneously. Customer concentration is real, GPU obsolescence is real, and near-term losses are widening.

On balance, I lean cautiously bullish. The contracts are signed, the capital is largely raised, and the upside asymmetry is unusual. This is a high-beta way to gain AI infrastructure exposure, and position sizing reflects that risk profile.

Contact [email protected] for any questions or corrections.

powered by

META buy

Buy Meta (NASDAQ: META). Muse Spark 1.3 is concrete proof of faster, cheaper agentic coding (fewer tool calls/tokens) and better long-horizon performance—exactly what Meta needs to turn AI spend into ad targeting, recommendations, and developer tools. BofA’s 32% upside case is supported by the valuation still lagging the earnings power implied by improved ad efficiency and lower inference costs from MTIA chips.

Key Risk: Meta’s AI upgrades fail to show up in ad pricing/engagement and margins—AI costs keep rising faster than revenue, so the multiple compresses.

GOOG buy

Buy Alphabet (NASDAQ: GOOG). If Meta’s agentic models improve ad targeting and developer tooling, the competitive pressure shifts to search/ads efficiency. Alphabet’s stronger cash generation and diversified ad stack let it defend share while benefiting from the industry’s push toward better AI-driven ad relevance and automation.

Key Risk: Meta’s AI actually boosts ad performance enough to take meaningful share and force Alphabet to spend more to catch up, hurting margins.

Meta stock NASDAQ:META jumped sharply after the company released Muse Spark 1.3, giving investors evidence that its AI spending may eventually produce returns.

The model is designed for coding and longer-running agentic tasks. Meta says it uses roughly 20% fewer tool calls and 25% fewer tokens than Muse Spark 1.2 in comparable engineering work.

Bank of America analyst Justin Post remains bullish. He has a Buy rating and an $810 price target, implying about 32% upside from Meta’s September 3 close of $610.68.

The debate is whether those advances can justify the infrastructure bill behind them.

Meta has spent much of 2026 facing questions over whether AI investment is outrunning commercially useful progress.

Muse Spark 1.3 gives bulls something more concrete.

Meta says the model handles longer-horizon tasks better, manages multiple workflows in one thread and improves coding efficiency. It is available through Muse Code and the Meta Model API.

Bernstein reiterated an Outperform rating and an $800 target, arguing that Meta’s AI-enhanced advertising engine remains a major advantage. The firm believes Meta is on track to rival or surpass Google Search in advertising revenue.

Meta does not need Muse Spark to become a standalone business on OpenAI’s scale.

Better models can improve recommendations, ad targeting, engagement and developer tools across Meta’s apps. The payoff can appear inside its existing profit engine rather than only through model sales.

Bank of America’s case rests on the gap between Meta’s execution and valuation.

Post highlighted Meta’s rapid model-release cadence and said the agentic improvements matter as the company develops a consumer AI agent internally known as Hatch.

There is also a hardware angle.

BofA estimates Meta’s planned MTIA custom-chip deployments could eventually represent 15% to 20% of its total AI capacity. Greater reliance on in-house silicon could lower computing costs as workloads expand.

At around $617 when BofA made its case, Meta traded near 18 times projected 2027 GAAP earnings, below its historical multiple of roughly 21 times and the broader market.

BofA’s $810 target is based on 24 times projected 2027 earnings.

The risk is that Meta’s AI bill remains enormous.

Its infrastructure push is raising fixed costs and pressuring margins and free cash flow, meaning new model releases must eventually translate into measurable economic returns.

KeyBanc remains constructive but more conservative, as the firm cut its target to $760 from $855 while keeping an Overweight rating.

KeyBanc said Meta Superintelligence Labs had made “meaningful progress” with Muse Spark and argued investors were “under-appreciating platform stickiness” among consumers and advertisers.

But the burden of proof keeps rising.

Investors will want evidence that Muse Spark gains adoption, that agents such as Hatch become useful products, and that MTIA chips reduce computing costs.

Alphabet's (GOOGL.O) Google on Tuesday rolled out changes to its online search results in Europe to satisfy EU antitrust regulators, a move which it said will degrade users' experience and ​ratchet up costs for European businesses.

The changes mark the largest reduction in quality of service ‌at the world's most popular internet search engine in its 29-year search history, Google official told Reuters.

Google said the EU pitched the changes as levelling the playing field for companies to advertise. However, Google said it sees that in reality the ​changes favour price comparison sites, also known as vertical search services (VSS), linked to sectors including ​hotels, airlines and restaurants, such as Expedia or Booking.com. They get more prominence in ⁠search results over companies in those sectors that are listed with just a link to their websites, ​telephone numbers and address.

The U.S. tech giant was hit with a €460 million ($534 million) fine in July for favouring ​its own services in shopping, hotels, transport and sports results in search results in breach of the EU's Digital Markets Act seeking to rein in the power of Big Tech.

The European Commission gave it 60 days to comply with the DMA ​or risk periodic penalty payments of up to 5% of its total worldwide turnover.

The revamped search results will ​highlight one specialised search engine at the top of the page, followed by two others with fewer details while a ‌carousel ⁠of hotels, airlines and restaurants for example will sit below them with key features such as real-time prices stripped out. The rankings will be determined by Google's algorithm.

"To comply with DMA requirements, we're making significant changes to Search in Europe," Nick Fox, Google's senior vice-president, knowledge & information, said in a statement to Reuters.

"These changes ​degrade the user experience for ​Europeans - boosting online intermediaries ⁠at the expense of local businesses, and removing helpful features people rely on every day. Users outside the EU will not be impacted by these changes," ​he said.

Google said past changes to comply with the DMA led to a ​30% drop in ⁠free, direct booking traffic to European businesses and the latest changes are expected to hit them.

The company said it has tested the changes with millions of users in Europe, which show a high level of dissatisfaction as ⁠they have ​to retype queries to find what they want.

Google has racked ​up total EU antitrust penalties of €10.38 billion over nearly two decades.

The EU fines drew fire from U.S. President Donald Trump who threatened to launch ​a probe into the bloc's "robbing" of American companies.

($1 = 0.8611 euros)

Nykredit A S bought a new position in Intel Corporation (NASDAQ:INTC – Free Report) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 1,222,470 shares of the chip maker’s stock, valued at approximately $170,693,000.

Other institutional investors have also added to or reduced their stakes in the company. Primecap Management Co. CA purchased a new stake in Intel during the second quarter valued at about $10,507,291,000. Norges Bank purchased a new position in shares of Intel in the 4th quarter worth about $2,233,159,000. Legal & General Group Plc purchased a new position in shares of Intel in the 2nd quarter worth about $4,096,110,000. Capital Research Global Investors increased its position in shares of Intel by 285.9% during the 4th quarter. Capital Research Global Investors now owns 26,619,928 shares of the chip maker’s stock valued at $982,279,000 after purchasing an additional 19,722,010 shares during the last quarter. Finally, Capital World Investors increased its position in shares of Intel by 20.3% during the 4th quarter. Capital World Investors now owns 104,060,268 shares of the chip maker’s stock valued at $3,839,833,000 after purchasing an additional 17,557,147 shares during the last quarter. Institutional investors own 64.53% of the company’s stock.

Intel Stock Performance Shares of INTC stock opened at $95.80 on Tuesday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.25 and a current ratio of 1.60. Intel Corporation has a fifty-two week low of $24.05 and a fifty-two week high of $142.35. The stock has a 50 day moving average price of $99.73 and a two-hundred day moving average price of $88.55. The company has a market capitalization of $483.22 billion, a P/E ratio of -45.40, a PEG ratio of 10.58 and a beta of 2.22.

Intel (NASDAQ:INTC – Get Free Report) last released its quarterly earnings data on Thursday, July 23rd. The chip maker reported $0.42 earnings per share for the quarter, beating analysts’ consensus estimates of $0.21 by $0.21. Intel had a positive return on equity of 2.62% and a negative net margin of 19.79%.The firm had revenue of $16.13 billion during the quarter, compared to analyst estimates of $14.43 billion. During the same quarter in the prior year, the firm posted ($0.10) earnings per share. The business’s quarterly revenue was up 25.2% compared to the same quarter last year. Intel has set its Q3 2026 guidance at 0.380-0.380 EPS. Analysts expect that Intel Corporation will post 1.01 earnings per share for the current year. Intel News Roundup Here are the key news stories impacting Intel this week:

Positive Sentiment: Intel CEO Lip-Bu Tan reportedly purchased approximately $10 million of Intel shares, a vote of confidence in the turnaround. The company’s latest quarter also showed revenue of about $16.1 billion, including strong data-center growth. Intel CEO share purchase and quarterly growth Positive Sentiment: Investors are broadening the AI trade beyond Nvidia. Intel gained alongside AMD as Nvidia lagged during the latest session, suggesting increased interest in alternative beneficiaries of AI infrastructure spending. AMD and Intel outperform Nvidia Positive Sentiment: Intel is positioning itself in enterprise and edge AI through contributions to the Linux Foundation’s TRACE open specification for trusted and verifiable AI workloads. The development could strengthen Intel’s role in secure AI infrastructure. Intel’s trusted AI standards efforts Neutral Sentiment: Some analysts remain bullish after Intel’s more than 140% 2026 rally, with one published target implying substantial additional upside. That optimism supports sentiment, but the size of the rally raises questions about whether expectations are already reflected in the stock. Intel upside forecast Negative Sentiment: A prominent Mizuho analyst lowered or reset Intel’s price target while comparing Intel with Arm. The move may weigh on shares because it signals that the recent rally could have outpaced near-term fundamentals. Analyst downgrades Intel price target Negative Sentiment: Nvidia’s expanding CPU and AI infrastructure strategy presents a competitive threat to Intel in data-center processors. Nvidia’s ecosystem investments, including a reported Intel stake, may support Intel financially but also make the company’s performance increasingly dependent on Nvidia-led demand. Nvidia CPU strategy and Intel competition Negative Sentiment: Intel’s comeback may require substantial capital and shareholder dilution, with one analysis highlighting a potential $23 billion dilution cost. Investors remain focused on whether manufacturing and AI investments can generate sufficient returns to justify that financing. Intel potential dilution analysis Analyst Ratings Changes A number of analysts recently weighed in on INTC shares. Moffett Nathanson downgraded Intel to a “neutral” rating in a research report on Thursday, June 11th. Sanford C. Bernstein reaffirmed a “market perform” rating and issued a $110.00 price objective on shares of Intel in a research note on Monday, July 27th. Robert W. Baird increased their target price on shares of Intel from $75.00 to $125.00 and gave the company a “neutral” rating in a report on Friday, July 24th. Wall Street Zen lowered shares of Intel from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Finally, Stifel Nicolaus decreased their target price on shares of Intel from $120.00 to $110.00 and set a “hold” rating on the stock in a research report on Friday, July 24th. One analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, thirty-one have assigned a Hold rating and three have issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $107.01.

Read Our Latest Research Report on Intel

Insiders Place Their Bets In other news, CEO Lip Bu Tan purchased 105,263 shares of the company’s stock in a transaction on Tuesday, August 11th. The stock was acquired at an average price of $95.00 per share, with a total value of $9,999,985.00. Following the transaction, the chief executive officer directly owned 1,314,669 shares of the company’s stock, valued at approximately $124,893,555. This represents a 8.70% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.05% of the stock is owned by insiders.

About Intel (Free Report)

Intel Corporation, founded in 1968 by Robert Noyce and Gordon E. Moore and headquartered in Santa Clara, California, is a leading global designer and manufacturer of semiconductor products. The company is historically notable for introducing the first commercial microprocessor and for driving the x86 architecture that underpins many personal computers and servers. Intel’s core business spans the design, fabrication and marketing of processors, chipsets and related components for a wide range of computing applications.

Intel’s product portfolio includes client and mobile processors marketed under brands such as Intel Core and Pentium, as well as high-performance Xeon processors for data centers and cloud infrastructure.

See Also Five stocks we like better than Intel 3 Under-the-Radar Defense Stocks With Record Backlogs This Korea ETF Has Soared, But the Rally May Not Be Over Why Guidewire’s Post-Earnings Plunge May Not Last Ride-Share Reckoning: Tesla Drives Into Uber’s Lane Want to see what other hedge funds are holding INTC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intel Corporation (NASDAQ:INTC – Free Report).

Receive News & Ratings for Intel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intel and related companies with MarketBeat.com's FREE daily email newsletter.

Public Employees Retirement System of Ohio purchased a new position in Gold.com Inc. (NYSE:GOLD – Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 35,148 shares of the company’s stock, valued at approximately $1,463,000. Public Employees Retirement System of Ohio owned 0.12% of Gold.com at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. Globeflex Capital L P bought a new position in Gold.com during the second quarter valued at $2,783,000. Bank of New York Mellon Corp bought a new stake in shares of Gold.com in the second quarter valued at $7,143,000. Bank of America Corp DE lifted its position in shares of Gold.com by 116.8% during the 1st quarter. Bank of America Corp DE now owns 60,575 shares of the company’s stock valued at $2,428,000 after buying an additional 32,637 shares during the last quarter. California State Teachers Retirement System lifted its position in shares of Gold.com by 69.2% during the 1st quarter. California State Teachers Retirement System now owns 29,031 shares of the company’s stock valued at $1,164,000 after buying an additional 11,871 shares during the last quarter. Finally, Empowered Funds LLC grew its stake in shares of Gold.com by 42.5% during the 1st quarter. Empowered Funds LLC now owns 277,029 shares of the company’s stock worth $11,103,000 after acquiring an additional 82,637 shares during the period. Hedge funds and other institutional investors own 62.85% of the company’s stock.

Analyst Upgrades and Downgrades Several equities research analysts recently weighed in on the company. Northland Securities set a $55.00 price objective on Gold.com in a report on Thursday. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Gold.com in a report on Monday, August 17th. Zacks Research lowered shares of Gold.com from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, July 1st. DA Davidson reiterated a “buy” rating and issued a $60.00 target price on shares of Gold.com in a research note on Thursday, September 3rd. Finally, Canaccord Genuity Group lowered their price target on shares of Gold.com from $70.00 to $65.00 and set a “buy” rating on the stock in a research report on Thursday. Four analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat.com, Gold.com presently has a consensus rating of “Moderate Buy” and a consensus target price of $58.00.

View Our Latest Stock Report on GOLD Gold.com Trading Up 0.1% NYSE:GOLD opened at $46.19 on Tuesday. Gold.com Inc. has a 1 year low of $22.00 and a 1 year high of $66.70. The stock’s fifty day moving average price is $42.62 and its two-hundred day moving average price is $44.34. The company has a debt-to-equity ratio of 0.11, a current ratio of 1.18 and a quick ratio of 0.29. The company has a market cap of $1.34 billion, a P/E ratio of 15.82 and a beta of 0.56.

Gold.com (NYSE:GOLD – Get Free Report) last announced its quarterly earnings results on Wednesday, September 2nd. The company reported $0.41 earnings per share for the quarter, missing the consensus estimate of $0.96 by ($0.55). Gold.com had a net margin of 0.32% and a return on equity of 18.15%. The company had revenue of $5.01 billion during the quarter, compared to analysts’ expectations of $5.67 billion. During the same quarter last year, the firm posted $0.41 earnings per share. As a group, analysts expect that Gold.com Inc. will post 3.73 EPS for the current year.

Gold.com Announces Dividend The business also recently announced a special dividend, which will be paid on Monday, September 28th. Shareholders of record on Wednesday, September 16th will be issued a dividend of $0.20 per share. The ex-dividend date of this dividend is Wednesday, September 16th. Gold.com’s payout ratio is presently 27.40%.

Gold.com Company Profile (Free Report)

Gold.com, Inc, together with its subsidiaries, operates as a precious metals company. It operates through three segments: Wholesale Sales & Ancillary Services, Direct-to-Consumer, and Secured Lending. The Wholesale Sales & Ancillary Services segment sells gold, silver, platinum, and palladium in the form of bars, plates, powders, wafers, grains, ingots, and coins. This segment also offers complementary services, such as receiving, handling, inventorying, processing, packing, and shipping of precious metals and custom coins on a secure basis; and designs and produces minted silver products.

Featured Articles Five stocks we like better than Gold.com 3 Under-the-Radar Defense Stocks With Record Backlogs This Korea ETF Has Soared, But the Rally May Not Be Over Why Guidewire’s Post-Earnings Plunge May Not Last Ride-Share Reckoning: Tesla Drives Into Uber’s Lane Want to see what other hedge funds are holding GOLD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gold.com Inc. (NYSE:GOLD – Free Report).

Receive News & Ratings for Gold.com Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gold.com and related companies with MarketBeat.com's FREE daily email newsletter.

EBay has launched an internal review of its shopping ​website's safeguards after Reuters flagged that several gender-prediction kits were available for delivery to India, where using them is a criminal offence ‌under a law meant to curb female foeticide.

After Reuters told eBay last week that nine listings on the platform showed gender-testing kits, including those made by brands such as SneakPeek and Peekaboo, being offered by third-party sellers for delivery in India, eBay removed these listings.

"These listings violated local regulations and eBay's policies, and we are reviewing these controls, including the relevant ​shipping and checkout experience, to determine whether further enhancements are appropriate," eBay told Reuters in a statement.

"EBay has controls in place intended to ​prevent certain gender-prediction products from being visible in India," it added.

EBay, which has 136 million active buyers globally, is one ⁠of the world's largest online marketplaces, where only third-party sellers list products. EBay does not have a local Indian shopping website but offers delivery to the ​country.

Platforms such as Amazon and eBay (EBAY.O) have previously come under scrutiny in India for listing restricted products, including banned wildlife items and e-cigarettes.

Amazon's U.S. website, which ships ​many products internationally to India, does list gender-testing products but does not offer India delivery, a Reuters review found.

THE INDIAN LAW
India's 1994 law on prenatal gender determination followed a sharp fall in the number of girls born for every 1,000 boys after the spread of ultrasound technology. Campaigners have said the technology let parents learn a foetus's sex early enough to ​abort female foetuses rather than raise a daughter.

The preference for male children is rooted in patrilineal inheritance customs, the expectation that sons support parents in their ​old age and dowry demands made at weddings by the groom and his family despite a decades-old ban on the practice.

Violations of the prenatal gender determination law can attract ‌up to ⁠three years in prison, with tougher penalties for repeat offences. India's health ministry did not respond to requests for comment on Reuters findings.

Cybersecurity firm FalconFeeds first flagged the eBay listings to Reuters. The listings offered the gender-testing kits priced from $6.99 to $156.59 and with delivery to India.

One listing on eBay offered the Peekaboo kit, made by U.S.-based DNA Diagnostics Center, and marketed on the website as "get your baby's gender at 6 weeks ... accurate and easy to use", with "FREE SHIPPING".

DNA Diagnostics Center told ​Reuters in a statement it does not ​sell or distribute the kits ⁠for resale in India, adding it does not control the actions of independent third parties once a product has been purchased.

SneakPeek did not respond to a request for comment.

INDIA TARGETS GOOGLE SEARCH RESULTS
In a sign of New Delhi's growing concerns ​about such products, Peekaboo — though not officially sold in India — has separately been named in two August 9 Indian ​government notices sent to ⁠Google, seeking removal of search results that link to the company's website.

The notices, reviewed by Reuters and sent by India's health ministry, said Google's India search engine provided "violative information" that led users to web pages "directly or indirectly promoting/advertising the gender prediction of an unborn child."

Search engines can typically block specific website links from appearing in results ⁠for users ​in a given country.

In the notices, the ministry attached screenshots of three Google searches — "peekaboo test," "buy peekaboo ​test online" and "boy or girl" — that linked to the Peekaboo website. It asked Google to discontinue the practice in line with Indian laws.

A Reuters check on Tuesday found the three searches returned results ​linking to the Peekaboo website.

Google and India's health ministry did not respond to Reuters queries.

Samsung and TSMC, the world's two biggest chipmakers, have committed to using ASML's High NA extreme ultraviolet (EUV) lithography machines, as demand grows for more advanced chips.

ASML's EUV lithography machines are critical tools that are used to print circuit patterns onto silicon wafers during the chipmaking process. The High NA machines can print smaller and more intricate patterns. This tool can cost around $400 million.

Samsung, one of the world's biggest memory chipmakers, said it would use ASML's machines to produce DRAM, a key type of memory, from 2028.

Samsung said it would adopt the technology in 2030, adding that it would "extend the DRAM scaling roadmap" and make the process more efficient.

ASML stock over the last 12 months.

TSMC said it would use ASML's tools for advanced chips and expects use of High NA machines to rise, "driven primarily by the increasingly complex transistor architectures required for AI applications."

Investors see the success of High NA EUV machines as key to ASML's future growth as the stock looks to extend a 120% run over the last year.

Barclays said in a note on Tuesday that the announcements "should provide more visibility on adoption which has been a key debate," adding that the news is "a positive."

Shares of Amsterdam-listed ASML were flat-to-lower in early trading on Tuesday.

Samsung and TSMC join Intel as customers for ASML's High NA machines. In July, ASML said that Intel is using the High NA EUV technology for advanced chip manufacturing.

ASML has not given a recent forecast on how many of the machines it expects to sell but has said that it will add about 30% capacity for EUV in total in 2027.

The analysts at Barclays said the announcements give ASML more visibility into planning.

"We see ASML with a significant decision ahead on whether to further expand EUV capacity than the recently expanded targets it has already given. Demand is clearly strong," Barclays said.

TSMC and Samsung will also join ASML in an industry initiative to advance next-generation 12-inch photmask technology, upgrading from the current 6-inch format. A key part of chip production, photomasks are effectively the stencils used to print the patterns on the wafers.

ASML said the benefits of a larger photomask include better productivity and lower chipmaking costs.

NEOS Investment Management LLC boosted its stake in shares of The Estee Lauder Companies Inc. (NYSE:EL – Free Report) by 14.0% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 40,191 shares of the company’s stock after buying an additional 4,932 shares during the period. NEOS Investment Management LLC’s holdings in Estee Lauder Companies were worth $3,173,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. REAP Financial Group LLC purchased a new stake in Estee Lauder Companies in the fourth quarter valued at approximately $27,000. Investors Towarzystwo Funduszy Inwestycyjnych Spolka Akcyjna purchased a new stake in shares of Estee Lauder Companies in the 4th quarter valued at $27,000. DV Equities LLC acquired a new position in Estee Lauder Companies during the 4th quarter worth about $36,000. Trust Co. of Vermont purchased a new position in Estee Lauder Companies during the 2nd quarter valued at about $28,000. Finally, Kozak & Associates Inc. acquired a new position in Estee Lauder Companies in the 2nd quarter valued at about $30,000. 55.15% of the stock is owned by institutional investors and hedge funds.

Insider Activity In related news, VP Rashida La Lande sold 7,766 shares of the company’s stock in a transaction dated Friday, August 28th. The stock was sold at an average price of $103.32, for a total value of $802,383.12. Following the completion of the sale, the vice president directly owned 14,357 shares of the company’s stock, valued at $1,483,365.24. This represents a 35.10% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 13.05% of the company’s stock.

Analysts Set New Price Targets Several research firms have recently commented on EL. Piper Sandler raised their price objective on shares of Estee Lauder Companies from $95.00 to $115.00 and gave the company an “overweight” rating in a research note on Thursday, August 20th. Morgan Stanley boosted their price target on shares of Estee Lauder Companies from $90.00 to $102.00 and gave the stock an “equal weight” rating in a research note on Thursday, August 20th. The Goldman Sachs Group increased their price objective on Estee Lauder Companies from $100.00 to $112.00 and gave the company a “buy” rating in a research note on Thursday, August 20th. Wells Fargo & Company boosted their target price on Estee Lauder Companies from $85.00 to $104.00 and gave the stock an “equal weight” rating in a research note on Thursday, August 20th. Finally, UBS Group increased their price target on Estee Lauder Companies from $86.00 to $106.00 and gave the company a “neutral” rating in a research report on Thursday, August 20th. Two investment analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating, twelve have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $104.67. Read Our Latest Research Report on Estee Lauder Companies

Estee Lauder Companies Stock Down 0.0% Estee Lauder Companies stock opened at $103.81 on Tuesday. The stock has a market cap of $37.56 billion, a PE ratio of 211.86, a P/E/G ratio of 1.20 and a beta of 1.28. The company has a debt-to-equity ratio of 1.79, a current ratio of 1.22 and a quick ratio of 0.90. The stock’s fifty day moving average is $89.04 and its two-hundred day moving average is $86.16. The Estee Lauder Companies Inc. has a 1-year low of $66.22 and a 1-year high of $121.64.

Estee Lauder Companies (NYSE:EL – Get Free Report) last issued its earnings results on Wednesday, August 19th. The company reported $0.39 earnings per share for the quarter, topping the consensus estimate of $0.32 by $0.07. The business had revenue of $3.64 billion for the quarter, compared to analyst estimates of $3.55 billion. Estee Lauder Companies had a return on equity of 23.52% and a net margin of 1.21%.The business’s quarterly revenue was up 6.3% on a year-over-year basis. During the same quarter last year, the company earned $0.09 EPS. Estee Lauder Companies has set its FY 2027 guidance at 3.100-3.350 EPS. On average, sell-side analysts expect that The Estee Lauder Companies Inc. will post 3.3 EPS for the current fiscal year.

Estee Lauder Companies Announces Dividend The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 15th. Shareholders of record on Monday, August 31st will be paid a $0.35 dividend. This represents a $1.40 annualized dividend and a yield of 1.3%. The ex-dividend date is Monday, August 31st. Estee Lauder Companies’s dividend payout ratio is currently 285.71%.

(Free Report)

Estée Lauder Companies Inc (NYSE: EL) is a global leader in prestige beauty that develops, manufactures and markets a broad portfolio of skincare, makeup, fragrance and hair care products. Founded in 1946 by Estée Lauder, the company has grown from a small family business into a multinational consumer-products enterprise headquartered in New York City. Its activities span product research and development, brand and product marketing, manufacturing and global distribution across multiple retail channels.

The company’s portfolio includes a mix of legacy and prestige brands that target different consumer segments and price points, with well-known names such as Estée Lauder, Clinique, MAC, La Mer and Jo Malone among others.

Read More Five stocks we like better than Estee Lauder Companies 3 Under-the-Radar Defense Stocks With Record Backlogs This Korea ETF Has Soared, But the Rally May Not Be Over Why Guidewire’s Post-Earnings Plunge May Not Last Ride-Share Reckoning: Tesla Drives Into Uber’s Lane

Receive News & Ratings for Estee Lauder Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Estee Lauder Companies and related companies with MarketBeat.com's FREE daily email newsletter.

Nykredit A S acquired a new stake in Strategy Inc (NASDAQ:MSTR – Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 27,417 shares of the software maker’s stock, valued at approximately $2,383,000.

Several other hedge funds also recently added to or reduced their stakes in the stock. Fideuram Asset Management Ireland dac purchased a new stake in shares of Strategy in the fourth quarter worth about $25,000. Westfuller Advisors LLC purchased a new stake in shares of Strategy during the 1st quarter valued at about $25,000. Ancora Advisors LLC raised its holdings in shares of Strategy by 111.7% during the 2nd quarter. Ancora Advisors LLC now owns 290 shares of the software maker’s stock valued at $25,000 after buying an additional 153 shares during the period. Wilkerson Advisory Group LLC acquired a new position in Strategy during the 4th quarter worth approximately $30,000. Finally, Binnacle Investments Inc lifted its position in Strategy by 492.9% during the 2nd quarter. Binnacle Investments Inc now owns 83 shares of the software maker’s stock worth $34,000 after acquiring an additional 69 shares in the last quarter. 59.84% of the stock is owned by hedge funds and other institutional investors.

Strategy Price Performance Shares of NASDAQ MSTR opened at $142.80 on Tuesday. Strategy Inc has a fifty-two week low of $81.81 and a fifty-two week high of $365.21. The business has a 50 day moving average price of $104.87 and a two-hundred day moving average price of $128.41. The company has a quick ratio of 5.39, a current ratio of 5.39 and a debt-to-equity ratio of 0.22. The firm has a market cap of $54.87 billion, a PE ratio of -1.47 and a beta of 3.59.

Strategy (NASDAQ:MSTR – Get Free Report) last announced its earnings results on Friday, July 31st. The software maker reported ($24.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.19) by ($22.26). The business had revenue of $122.37 million during the quarter, compared to analyst estimates of $122.90 million. Strategy had a negative net margin of 6,102.95% and a negative return on equity of 74.18%. The business’s revenue for the quarter was up 6.9% on a year-over-year basis. During the same period in the previous year, the company earned $32.52 earnings per share. Sell-side analysts expect that Strategy Inc will post -23.74 earnings per share for the current fiscal year. Insider Buying and Selling In related news, CEO Phong Le acquired 11,000 shares of Strategy stock in a transaction on Monday, June 22nd. The shares were purchased at an average cost of $90.80 per share, for a total transaction of $998,800.00. Following the purchase, the chief executive officer directly owned 11,000 shares of the company’s stock, valued at $998,800. The trade was a ∞ increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Jarrod M. Patten sold 1,850 shares of the firm’s stock in a transaction on Thursday, August 27th. The stock was sold at an average price of $130.00, for a total transaction of $240,500.00. Following the transaction, the director directly owned 28,406 shares of the company’s stock, valued at approximately $3,692,780. This represents a 6.11% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 13,950 shares of company stock valued at $1,615,809 in the last three months. Corporate insiders own 6.49% of the company’s stock.

Strategy News Summary Here are the key news stories impacting Strategy this week:

Positive Sentiment: An analyst argues that Strategy’s stock could nearly triple, citing the company’s Bitcoin holdings and the potential for a significant recovery in the cryptocurrency. This provides an upside narrative for investors despite the stock’s substantial decline over the past year. Strategy Is Down More Than 50% in 12 Months Positive Sentiment: Strategy purchased 4,603 Bitcoin for approximately $370 million, reinforcing its position as a leveraged corporate bet on Bitcoin. Bitcoin trading near $80,000 and continued corporate demand could support the value of Strategy’s holdings and improve investor sentiment. Bitcoin Trades Near $80,000 Neutral Sentiment: A Hyperliquid trader’s heavily underwater Strategy short highlights intense positioning and volatility around MSTR. Forced covering could provide short-term support, but the report does not change Strategy’s underlying fundamentals. Trader Wins 26 Bets in a Row Negative Sentiment: Shares recently decreased after the Bitcoin acquisition, with coverage reporting a decline of about 4.2%. Investors may be concerned that continued purchases increase exposure to Bitcoin’s volatility, while Saylor’s bullish commentary and upcoming U.S. crypto legislation add further event risk. Strategy Stock Drops Following Bitcoin Purchase Negative Sentiment: Strategy’s dependence on Bitcoin means its valuation can move sharply with cryptocurrency prices and market risk appetite. The company’s latest reported quarter also included a large loss and a significant earnings miss, adding to concerns about financial volatility. Analyst Ratings Changes Several analysts have issued reports on the stock. Canaccord Genuity Group increased their price objective on shares of Strategy from $130.00 to $175.00 and gave the company a “buy” rating in a research report on Tuesday, August 25th. HC Wainwright set a $325.00 target price on shares of Strategy in a research report on Monday, August 3rd. Alliance Global Partners initiated coverage on shares of Strategy in a research note on Tuesday, September 1st. They issued a “buy” rating and a $217.00 target price for the company. TD Cowen lowered their price target on shares of Strategy from $400.00 to $260.00 and set a “buy” rating for the company in a report on Tuesday, June 30th. Finally, Sanford C. Bernstein reaffirmed an “outperform” rating and set a $350.00 price target (down from $450.00) on shares of Strategy in a report on Wednesday, August 26th. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Strategy has a consensus rating of “Moderate Buy” and an average target price of $236.41.

View Our Latest Stock Analysis on Strategy

Strategy Profile (Free Report)

Strategy, formerly known as MicroStrategy, Incorporated (NASDAQ: MSTR) is a global provider of enterprise analytics and mobility software. The company’s flagship platform offers business intelligence, data discovery, and advanced visualizations that enable organizations to analyze large volumes of data and deliver actionable insights. In addition to traditional on-premises deployments, Strategy provides a range of cloud-based services and managed offerings that allow customers to leverage the power of its analytics tools without managing complex infrastructure.

Founded in 1989 by Michael J.

See Also Five stocks we like better than Strategy 3 Under-the-Radar Defense Stocks With Record Backlogs This Korea ETF Has Soared, But the Rally May Not Be Over Why Guidewire’s Post-Earnings Plunge May Not Last Ride-Share Reckoning: Tesla Drives Into Uber’s Lane Want to see what other hedge funds are holding MSTR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Strategy Inc (NASDAQ:MSTR – Free Report).

Receive News & Ratings for Strategy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strategy and related companies with MarketBeat.com's FREE daily email newsletter.

Hsbc Holdings PLC lowered its stake in CubeSmart (NYSE:CUBE – Free Report) by 31.4% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 855,192 shares of the real estate investment trust’s stock after selling 391,687 shares during the quarter. Hsbc Holdings PLC owned 0.38% of CubeSmart worth $34,085,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in the stock. BlackRock Inc. bought a new position in shares of CubeSmart in the second quarter worth approximately $1,349,164,000. Norges Bank bought a new stake in CubeSmart during the 4th quarter valued at $395,968,000. Canada Pension Plan Investment Board bought a new stake in CubeSmart during the 2nd quarter valued at $288,512,000. Bank of New York Mellon Corp purchased a new stake in CubeSmart during the 2nd quarter valued at $74,199,000. Finally, Millennium Management LLC boosted its position in CubeSmart by 201.5% during the 4th quarter. Millennium Management LLC now owns 2,739,600 shares of the real estate investment trust’s stock valued at $98,763,000 after buying an additional 1,830,993 shares during the period. Hedge funds and other institutional investors own 97.61% of the company’s stock.

Wall Street Analyst Weigh In A number of equities analysts have issued reports on the stock. Raymond James Financial started coverage on shares of CubeSmart in a research report on Wednesday, July 15th. They issued an “outperform” rating and a $44.00 price objective on the stock. KeyCorp reiterated a “sector weight” rating on shares of CubeSmart in a report on Tuesday, August 4th. Royal Bank Of Canada reiterated an “outperform” rating and set a $47.00 target price on shares of CubeSmart in a report on Tuesday, August 4th. Mizuho cut their target price on CubeSmart from $42.00 to $41.00 and set a “neutral” rating on the stock in a research note on Wednesday, September 2nd. Finally, UBS Group boosted their price target on CubeSmart from $41.00 to $43.00 and gave the company a “neutral” rating in a report on Friday, July 10th. Six investment analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $43.45.

Check Out Our Latest Research Report on CUBE CubeSmart Price Performance Shares of NYSE CUBE opened at $39.51 on Tuesday. CubeSmart has a 1 year low of $35.09 and a 1 year high of $43.26. The company has a debt-to-equity ratio of 1.34, a current ratio of 0.07 and a quick ratio of 0.07. The company’s 50-day moving average is $40.93 and its 200 day moving average is $39.98. The stock has a market capitalization of $8.90 billion, a P/E ratio of 27.25, a P/E/G ratio of 6.50 and a beta of 1.05.

CubeSmart (NYSE:CUBE – Get Free Report) last issued its quarterly earnings data on Thursday, July 30th. The real estate investment trust reported $0.39 EPS for the quarter, missing the consensus estimate of $0.64 by ($0.25). The company had revenue of $286.49 million during the quarter, compared to analysts’ expectations of $281.12 million. CubeSmart had a return on equity of 12.35% and a net margin of 29.41%.The business’s quarterly revenue was up 1.5% on a year-over-year basis. During the same quarter last year, the business earned $0.65 earnings per share. CubeSmart has set its Q3 2026 guidance at 0.640-0.660 EPS and its FY 2026 guidance at 2.540-2.600 EPS. On average, sell-side analysts expect that CubeSmart will post 2.57 earnings per share for the current year.

CubeSmart Announces Dividend The company also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Thursday, October 1st will be paid a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a dividend yield of 5.4%. The ex-dividend date is Thursday, October 1st. CubeSmart’s dividend payout ratio (DPR) is presently 146.21%.

About CubeSmart (Free Report)

CubeSmart (NYSE: CUBE) is a publicly traded real estate investment trust (REIT) specializing in the ownership, operation and management of self-storage facilities across the United States. The company’s portfolio comprises properties in primary and secondary markets, catering to both individual and business customers seeking flexible, short-term and long-term storage solutions. CubeSmart’s facilities feature a range of unit sizes, climate-controlled options and advanced security features, supported by on-site managers and centralized customer service operations.

In addition to traditional self-storage units, CubeSmart offers specialty services such as vehicle and boat storage, retail sales of packing and moving supplies, and tenant insurance programs.

Featured Stories Five stocks we like better than CubeSmart 3 Under-the-Radar Defense Stocks With Record Backlogs This Korea ETF Has Soared, But the Rally May Not Be Over Why Guidewire’s Post-Earnings Plunge May Not Last Ride-Share Reckoning: Tesla Drives Into Uber’s Lane Want to see what other hedge funds are holding CUBE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CubeSmart (NYSE:CUBE – Free Report).

Receive News & Ratings for CubeSmart Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CubeSmart and related companies with MarketBeat.com's FREE daily email newsletter.

Hsbc Holdings PLC increased its position in shares of Williams-Sonoma, Inc. (NYSE:WSM – Free Report) by 12.1% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 302,105 shares of the specialty retailer’s stock after buying an additional 32,644 shares during the period. Hsbc Holdings PLC owned 0.26% of Williams-Sonoma worth $70,540,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Caitong International Asset Management Co. Ltd acquired a new position in shares of Williams-Sonoma in the fourth quarter worth about $25,000. Atlantic Union Bankshares Corp grew its position in shares of Williams-Sonoma by 51.5% during the 4th quarter. Atlantic Union Bankshares Corp now owns 147 shares of the specialty retailer’s stock valued at $26,000 after acquiring an additional 50 shares during the period. MidFirst Bank acquired a new stake in shares of Williams-Sonoma during the 4th quarter valued at about $30,000. Ballast Advisors LLC purchased a new position in shares of Williams-Sonoma in the 1st quarter valued at about $30,000. Finally, Millstone Evans Group LLC increased its stake in shares of Williams-Sonoma by 229.4% in the 1st quarter. Millstone Evans Group LLC now owns 168 shares of the specialty retailer’s stock valued at $31,000 after purchasing an additional 117 shares in the last quarter. Institutional investors and hedge funds own 99.29% of the company’s stock.

Wall Street Analyst Weigh In WSM has been the topic of a number of recent analyst reports. Barclays set a $190.00 price target on Williams-Sonoma and gave the stock an “equal weight” rating in a research report on Friday, May 22nd. The Goldman Sachs Group restated a “buy” rating and issued a $261.00 price objective (up from $230.00) on shares of Williams-Sonoma in a research report on Tuesday, August 11th. UBS Group reaffirmed a “neutral” rating and set a $247.00 target price (up from $190.00) on shares of Williams-Sonoma in a research note on Thursday, August 27th. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $260.00 target price on shares of Williams-Sonoma in a research note on Thursday, August 27th. Finally, Morgan Stanley increased their target price on Williams-Sonoma from $210.00 to $240.00 and gave the company an “equal weight” rating in a research report on Thursday, August 27th. Ten research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the stock. Based on data from MarketBeat.com, Williams-Sonoma currently has a consensus rating of “Moderate Buy” and a consensus price target of $245.56.

Check Out Our Latest Research Report on WSM Williams-Sonoma Price Performance NYSE WSM opened at $227.12 on Tuesday. The company has a market cap of $26.75 billion, a PE ratio of 23.25, a price-to-earnings-growth ratio of 2.45 and a beta of 1.47. The stock’s 50 day simple moving average is $232.29 and its 200-day simple moving average is $208.92. Williams-Sonoma, Inc. has a 1-year low of $165.51 and a 1-year high of $254.89.

Williams-Sonoma (NYSE:WSM – Get Free Report) last issued its quarterly earnings results on Wednesday, August 26th. The specialty retailer reported $2.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.08 by $0.02. Williams-Sonoma had a return on equity of 53.48% and a net margin of 14.73%.The firm had revenue of $1.96 billion for the quarter, compared to analyst estimates of $1.93 billion. During the same period in the previous year, the company posted $2.00 earnings per share. The business’s revenue was up 6.7% on a year-over-year basis. On average, equities research analysts anticipate that Williams-Sonoma, Inc. will post 9.48 EPS for the current fiscal year.

Williams-Sonoma Announces Dividend The firm also recently announced a quarterly dividend, which was paid on Friday, August 21st. Shareholders of record on Friday, July 17th were paid a dividend of $0.76 per share. This represents a $3.04 annualized dividend and a yield of 1.3%. The ex-dividend date of this dividend was Friday, July 17th. Williams-Sonoma’s payout ratio is 31.12%.

Insider Transactions at Williams-Sonoma In other news, EVP Karalyn Yearout sold 522 shares of the stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $246.39, for a total value of $128,615.58. Following the completion of the sale, the executive vice president directly owned 20,195 shares in the company, valued at $4,975,846.05. This represents a 2.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 2,634 shares of company stock worth $632,696. Insiders own 1.10% of the company’s stock.

Williams-Sonoma Profile (Free Report)

Williams‑Sonoma, Inc is a specialty retailer focused on the home and culinary markets, best known for premium cookware, kitchen tools and home furnishings. The company traces its roots to a single cookware store founded by Chuck Williams in 1956 in Sonoma, California, and has evolved into a multi‑brand home furnishings and housewares business. Its merchandise mix spans cookware and kitchen electrics, tabletop and food prep items, furniture, bedding, lighting and decorative accessories designed for both everyday use and higher‑end interiors.

The company operates a portfolio of consumer brands that target distinct segments of the home market.

See Also Five stocks we like better than Williams-Sonoma 3 Under-the-Radar Defense Stocks With Record Backlogs This Korea ETF Has Soared, But the Rally May Not Be Over Why Guidewire’s Post-Earnings Plunge May Not Last Ride-Share Reckoning: Tesla Drives Into Uber’s Lane Want to see what other hedge funds are holding WSM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Williams-Sonoma, Inc. (NYSE:WSM – Free Report).

Receive News & Ratings for Williams-Sonoma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Williams-Sonoma and related companies with MarketBeat.com's FREE daily email newsletter.

Aptos has rolled out Confidential APT on its mainnet, giving users the ability to encrypt their token balances and transfer amounts without hiding who’s transacting. It’s a deliberate design choice: privacy where it matters for business, transparency where regulators demand it.

The feature, now integrated into the Petra Wallet, operates as a 1:1 wrapped version of APT. Users opt in to shield their balances from public view while their wallet addresses remain fully visible on-chain.

How it works under the hood Confidential APT leans on two cryptographic heavyweights: zero-knowledge proofs and homomorphic encryption. Zero-knowledge proofs let one party prove a statement is true without revealing the underlying data. Homomorphic encryption goes a step further, allowing computations on encrypted data without ever decrypting it.

Together, these techniques mean the Aptos network can verify that a transfer is valid, that the sender has sufficient funds, and that no tokens are being conjured from thin air. All without anyone on-chain seeing the actual numbers involved.

At launch, only the native APT token is eligible for confidential transactions. The underlying standard, however, was built to extend to other tokens pending future governance votes.

Advertisement

The compliance play Aptos is explicitly pitching Confidential APT at compliance-heavy use cases: payroll processing, corporate treasury management, and business-to-business settlements.

Consider the payroll scenario. A company paying employees on-chain currently broadcasts every salary to anyone with a block explorer. Confidential APT lets the payment go through with cryptographic proof of validity while keeping the dollar amount between employer and employee.

The same logic applies to B2B settlements, where companies have obvious reasons to keep transaction sizes private from competitors monitoring on-chain activity. Treasury operations face similar exposure risks when large movements signal strategy to the market before leadership is ready to disclose.

For users who don’t want or need privacy, nothing changes. The feature is entirely opt-in, meaning the default transparent experience remains untouched.

Governance approval and early traction Confidential APT didn’t appear overnight. The feature was activated following Proposal #188, which went through governance voting around April 24-25, 2026. The proposal received near-unanimous support from the community.

The official wallet integration announcements came on August 4, 2026, when the Petra Wallet confirmed support for confidential transactions. By mid-August 2026, roughly 15,000 APT had already moved into confidential pools.

Aptos itself has been building momentum on the infrastructure side. The mainnet originally launched in October 2022, and by April 2026, daily transaction volumes had surpassed 8 million.

Extending the privacy standard to other tokens, stablecoins being the obvious next candidate, would require a separate governance proposal and community vote.

What this means for the broader market Privacy in crypto has always been politically charged. Tornado Cash sanctions, Monero delistings, and ongoing regulatory scrutiny of mixing services have made the topic radioactive for many projects. Aptos is betting it can thread the needle by offering selective privacy that satisfies business needs without triggering the alarm bells that fully private transactions set off.

The fact that addresses remain visible provides a strong defense, since law enforcement can still trace the flow of funds between wallets even if individual amounts are encrypted.

Disclosure: This article was edited by Editorial Team. For more information on how we create and review content, see our Editorial Policy.

Volkswagen zvažuje v rámci rozsáhlé reorganizace svého portfolia prodej italského výrobce motocyklů Ducati, který od roku 2012 patří pod značku Audi. Případný prodej by zapadal do širšího plánu zjednodušení struktury koncernu a zvýšení efektivity hospodaření. Hodnota společnosti by podle odhadů mohla dosahovat přibližně 1,25 miliardy eur.

Německý automobilový koncern Volkswagen zvažuje, že v rámci rozsáhlé reorganizace svého portfolia prodá italského výrobce motocyklů Ducati, který je součástí skupiny Audi. V rozhovoru s agenturou Bloomberg to řekl generální ředitel Audi Gernot Döllner. Audi patří do koncernu Volkswagen. Hodnota Ducati by podle Bloombergu mohla činit 1,25 miliardy eur (30,2 miliardy Kč). Koncern Volkswagen má zhruba 2000 podniků. Ducati patří mezi zhruba 600, u kterých vedení koncernu teď prověřuje, zda si je nadále ponechá.

"V rámci koncernu Volkswagen jsme se zavázali k disciplinovanému a zodpovědnému řízení portfolia," uvedl Döllner. "Součástí hodnoticího procesu je i diskuse o Ducati, ale zatím nebylo nic rozhodnuto," dodal.

Volkswagen se nyní snaží zeštíhlit, aby se stal konkurenceschopnějším. Dozorčí rada minulý týden schválila restrukturalizační balíček, který počítá se zmenšením portfolia podniků zhruba o třetinu. V červnu se skupina dohodla na prodeji 51procentního podílu v divizi lodních motorů Everllence. Měla by tak získat zhruba 7,4 miliardy eur.

Automobilka Audi koupila firmu Ducati v roce 2012. Automobilka zvažovala prodej tohoto téměř 100 let starého výrobce motocyklů už v roce 2017, od záměru ale nakonec odstoupila kvůli nesouhlasu německých odborů. Firma Ducati si od té doby upevnila pozici na trhu a stala se jednou z dominantních značek v motocyklových závodech. Díky svému úspěchu získala v motocyklovém světě auru podobnou té, jakou má Ferrari, a má své věrné příznivce, kteří si říkají Ducatisti.

Případný prodej by měl zvláštní symbolický význam pro rodinný klan Porsche-Piëch, který vlastní kontrolní podíl ve Volkswagenu. Zesnulý patriarcha Ferdinand Piëch byl motocyklovým nadšencem, osobně se zasazoval o akvizici v roce 2012 a později působil v představenstvu Ducati. Provozní marže motocyklové značky však nedosahuje devítiprocentního cíle, kterého chce generální ředitel Volkswagenu Oliver Blume dosáhnout v rámci celé skupiny do roku 2030.

Ducati ročně prodá kolem 50.000 motocyklů. Tržby firmy loni činily 925 milionů eur a provozní zisk 52 milionů eur.

Döllner v rozhovoru s agenturou Bloomberg také řekl, že Audi stále zvažuje možnosti výroby ve Spojených státech. V současné době tam Audi žádná auta nevyrábí, automobilka je tak vystavena většímu riziku než konkurenční společnosti BMW a Mercedes-Benz. Automobilka Audi by v USA mohla využít kapacit stávající továrny Volkswagenu nebo nového závodu společnosti Scout Motors. Jakýkoliv krok bude součástí širší restrukturalizace výrobní sítě koncernu.

Prefer us on Google

Summary:

The AUD/JPY currency pair dipped to a four-week low, even as iron ore prices climbed. This drop largely came from a stronger Japanese yen and a pullback in global carry trades Signals from the BoJ hint at a possible interest rate hike in September, boosting the yen and making currency intervention less likely. Meanwhile, the RBA holds at 4.35%, pointing at stubborn inflation The AUD/JPY's downward slide could extend into September. This depends on the BoJ confirming monetary tightening and China's economic data staying weak The Australian dollar dropped against the Japanese yen this week, which might seem a bit odd. After all, Australia’s main export, iron ore, recently topped US$100 per tonne, reaching its highest intraday price since early July.

Normally, strong commodity prices like that would boost the Aussie dollar. Yet, the AUD/JPY exchange rate has instead fallen to four-week lows, slipping below 111.00. So, what’s going on?

Why Has AUD/JPY Turned Bearish? The AUD/JPY isn’t weakening because Australia’s economy is struggling. Instead, it’s the Japanese yen that’s gaining significant strength. Talk of the Bank of Japan (BoJ) raising interest rates has surged after central bank officials made clear statements, even hinting at possible consecutive rate hikes.

With Japan’s GDP and wage growth picking up, market watchers now expect a 25-basis-point rate increase to 1.25% at the next BoJ policy meeting. Plus, the Ministry of Finance’s interventions in July and August, which caused a record drop in foreign reserves, also helped the yen rebound from multi-year lows.

As the interest rate gap narrows and Japanese yields climb, carry trades, which once favored the higher-yielding Australian dollar, are unwinding much faster.

What this Means For BoJ and RBA Decisions For the BoJ, a consistently strong yen means less immediate pressure to intervene further in the currency market. This also aligns with their plan for a gradual return to normal policy.

A stronger yen helps manage import costs, letting the central bank focus on domestic inflation trends. Markets have already priced in a September rate hike. Any further increases later this year will probably hinge on new data regarding wages, services inflation, and economic growth.

The Reserve Bank of Australia (RBA) faces a different set of considerations. Strong commodity prices certainly help the nation’s terms of trade, but a weaker currency against key Asian trading partners could push up imported inflation.

Still, with domestic economic indicators looking stable, the RBA isn’t expected to change its policy cash rate. Their focus remains on controlling inflation, rather than directly managing the currency.

All eyes will be on the RBA’s policy meeting in late September, awaiting any shifts in its economic outlook. Another rate hike remains possible if domestic data stays strong, though markets currently see only a moderate chance of this happening.

Will the Downturn Extend? The AUD/JPY pair will likely continue facing downward pressure in the short term. Should the BoJ confirm an interest rate hike, combined with any signs of weaker activity in China or less demand for iron ore, the pair could drop towards lower support levels around 110.

A stronger yen would also make carry trades less appealing. Conversely, stronger-than-expected Australian economic data or new stimulus from China might help stabilize the Australian dollar.

This downward trend for AUD/JPY appears set to continue through September, primarily driven by central bank policy decisions.

The long-term trajectory will depend on improvements in iron ore markets and the pace at which the BoJ normalizes policy relative to the RBA. Both central banks’ September meetings should offer significant insight into these future directions.

Why is AUD/JPY falling even though iron ore prices are rising?

The yen’s strength is pulling the pair lower. This isn’t about Australian fundamentals. Instead, it’s driven by hawkish Bank of Japan signals, including expectations for a rate hike and the impact of past interventions.

Why has AUD/JPY fallen despite higher iron ore prices?

The Australian dollar saw some temporary support from higher iron ore prices. But market expectations for a Bank of Japan rate hike, coupled with a stronger yen had more sway.

How might this affect Bank of Japan decisions?

A stronger yen reduces the need for direct currency intervention. It also helps the BoJ pursue steady rate increases, focusing on domestic inflation rather than just defending the currency.

With shares down 61% from its 52-week high, it's a good time to look at Archer Aviation (ACHR -0.87%) stock. And here's an interesting angle: Its second-quarter revenue was $5 million, and none of it came from carrying passengers. Most of it came from fueling, ground handling, and leasing space at Hawthorne Airport in Los Angeles, which Archer operates. A year earlier, revenue was zero.

In other words, a market value of about $4.4 billion rests on an air taxi service that hasn't started.

My prediction: Midnight -- Archer's electric vertical takeoff and landing (eVTOL) aircraft -- carries its first paying passenger in the United States before 2028.

Image source: Archer Aviation.

Certification is in its final phaseArcher describes the FAA's route to a type certificate as a four-phase process, and it says it's now in the last one. The company announced in May that it had become the first eVTOL maker to close Phase 3. Phase 4 is where compliance with the FAA's airworthiness requirements gets demonstrated through formal testing. It's the step that ends with a type certificate.

And in July, a piloted Midnight flew a round trip between Salinas Municipal Airport and Monterey Regional Airport, each leg taking about nine minutes -- the company's first intercity flights in California.

Archer was also selected as an air taxi partner in three winning applications covering eight states under the White House's eVTOL Integration Pilot Program (eIPP).

"[W]e plan to begin flying in the Los Angeles area based out of Hawthorne Airport, and subsequently commence operations under the White House's eIPP later this year in Texas," CEO Adam Goldstein said in the company's second-quarter shareholder letter.

There's a hard date, too. Archer is the Official Air Taxi Provider of the LA28 Olympic Games in the summer of 2028, a role that would be hard to fill without passenger service running by then.

Can the money reach the date?The bigger threat to the date is money. Archer's net loss was $263.2 million in the second quarter, up about 28% year over year and up from $217.7 million in the first quarter. Management guided to a third-quarter adjusted EBITDA loss of $170 million to $200 million, after a $177.1 million loss on that basis in the second quarter. (Adjusted EBITDA, the profit measure Archer guides on, excludes items such as stock-based compensation.) The losses are widening as flight testing, certification work, and production spending all ramp.

The balance sheet can absorb it for a while. Archer ended June with about $1.6 billion of cash and short-term investments, down about $215 million for the quarter. At that pace of cash use, the money covers about seven more quarters. That clock runs into 2028.

Of course, Archer also agreed in August to buy three subsidiaries from Boeing, paying in stock and warrants, with closing expected by year-end. Integration is rarely free, and more stock sales seem likely.

But I don't think the prediction hinges on raising more money -- the cash already on hand can carry Archer to a first paying flight.

The UAE could come firstNotably, the first fare may not be American. In May, the United Arab Emirates' aviation regulator moved Midnight into a Restricted Type Certificate program, a streamlined path that allows limited commercial operations there. Service is planned in Abu Dhabi, so Archer's first paying passenger anywhere could board overseas, possibly before the FAA finishes its work.

That's why the call is scoped to the United States. After all, a fare in Abu Dhabi would validate the aircraft. But the U.S. path runs through the FAA, and the home market is the one the investment case rests on.

The honest risk is the schedule. Archer said with its fourth-quarter report that it was targeting its first passenger-carrying flights in 2026, and a target is not a schedule -- Archer still has to fly the tests, and the FAA has to sign off.

Premium Feature

Moneyball Superscore

59/100

Today's Change

(

-0.87

%) $

-0.05

Current Price

$

5.71

But the call doesn't need 2026 to hold. Between management's late-2026 plans and the end of 2027 sits a year of slack.

So, will a paying passenger board a Midnight in the U.S. before 2028? I think so. Archer says it closed Phase 3 of the FAA's process before any other eVTOL company. The pilot program gives it somewhere to fly this year, and the balance sheet reaches the date without help.

The prediction and the stock are different bets, though. At about $4.4 billion, Archer is still valued on what the service could become, and the losses are widening while shareholders wait.

I'd want to see what a paying route earns before buying shares.

Please see below information about transactions made under the third tranche of the 2026 share buy-back programme for Equinor ASA (OSE:EQNR, NYSE:EQNR, CEUX:EQNRO, TQEX:EQNRO).

Date on which the buy-back tranche was announced: 22 July 2026.

The duration of the buy-back tranche: 23 July to no later than 26 October 2026.

Further information on the tranche can be found in the stock market announcement on its commencement dated 22 July 2026, available here: https://newsweb.oslobors.no/message/678529

From 31 August to 4 September 2026, Equinor ASA has purchased a total of 700,000 own shares at an average price of NOK 400.9647 per share.

Overview of transactions:

DateTrading venueAggregated daily volume (number of shares)Daily weighted average share price (NOK)Total daily transaction value (NOK)     31 AugustOSE142,000397.542656,451,049.20 CEUX    TQEX        1 SeptemberOSE140,000403.711956,519,666.00 CEUX    TQEX        2 SeptemberOSE138,000405.826556,004,057.00 CEUX    TQEX        3 SeptemberOSE140,000401.640056,229,600.00 CEUX    TQEX        4 SeptemberOSE140,000396.220955,470,926.00 CEUX    TQEX        Total for the periodOSE700,000400.9647280,675,298.20 CEUX    TQEX        Previously disclosed buy-backs under the trancheOSE3,648,520385.54871,406,682,284.31CEUX   TQEX   Total3,648,520385.54871,406,682,284.31     Total buy-backs under the tranche (accumulated)OSE4,348,520388.03031,687,357,582.51CEUX   TQEX   Total4,348,520388.03031,687,357,582.51 Following completion of the above transactions, Equinor ASA owns a total of 18,803,431 own shares, corresponding to 0.79% of Equinor ASA’s share capital, including shares under Equinor’s share savings programme (excluding shares under Equinor’s share savings programme, Equinor owns a total of 7,883,495 own shares, corresponding to 0.33% of the share capital).

This is information that Equinor ASA is obliged to make public pursuant to the EU Market Abuse Regulation and that is subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act.

Appendix: A overview of all transactions made under the buy-back tranche that have been carried out during the above-mentioned time period is attached to this report and available at www.newsweb.no.

Contact details:

Investor relations
Bård Glad Pedersen, senior vice president Investor Relations,
+47 918 01 791

Media
Sissel Rinde, vice president Media Relations,
+47 412 60 584

Detailed overview of transactions

Slovenia has approved Tesla’s (TSLA.O) FSD driver-assistance system for use on its roads, the ​U.S. automaker said, becoming the sixth European ‌country to do so ahead of a potential EU-wide vote.

"FSD Supervised now approved in Slovenia. Rollout will begin ​soon," Tesla wrote in a post on X ​on Monday that was reposted by CEO ⁠Elon Musk.

Slovenia's Energy and Infrastructure Minister Jernej Vrtovec ​also reposted the announcement with the words "Developing Slovenia".

Regulators ​provisionally approved the use of the software on roads in the Netherlands in early April, making it the ​first country in the EU to allow ​FSD, which can control a car but requires drivers to ‌pay ⁠attention.

Tesla said last week, when it publicly released a self-produced dataset from its European and North American testing, that an EU-wide approval vote could ​happen as soon ​as ⁠October 6.

Besides the Netherlands and Slovenia, four other European countries have approved Tesla's ​driver-assistance system, while Finland and Greece have ​said they ⁠are considering approvals.

France, which raised issues in July around potential approvals due to safety concerns, said last ⁠week ​it had begun testing two ​FSD-equipped cars following what its transport minister called a "constructive exchange" with ​Musk.

PARIS, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Magnite (NASDAQ:MGNI), the largest independent sell-side advertising company, today announced the launch of its first agentic campaign in EMEA in collaboration with the trading desk, Amnet France. The results offer a real-world look at the benefits agentic buying can have on improving the outcomes of premium CTV campaigns.

Using natural language prompts, Amnet leveraged Magnite’s buyer agent to build and activate a video campaign through ClearLine on behalf of a leading automotive manufacturer. Through Magnite Orchestration, the Magnite buyer agent communicated with the Magnite seller agent to identify and activate relevant premium CTV supply aligned with the campaign objectives, streamlining the path from buyer intent to execution. Rather than manually configuring campaign settings, identifying publishers and creating deal structures, the Amnet team was able to spend more time focused on strategy.

The results included an approximate 70% reduction in campaign setup time and a strong video view-through rate (VTR) of 95. The agent also surfaced relevant inventory and optimisation opportunities that may not have been identified through traditional manual workflows, helping teams make more informed campaign decisions.

Barbara Thuillier-Romeri, Ad-Tech Manager, Amnet France said: "As AI continues to mature, we wanted to understand how agentic technology could deliver practical value and complement the way we operate today. Working with Magnite gave us the opportunity to evaluate how their buyer agent could enhance the way our teams execute campaigns and drive stronger outcomes. We look forward to leveraging more of the product’s capabilities going forward, and are excited by the potential for this to evolve how we approach campaigns.”

“AI is only as valuable as the inventory and data it can access," added Edouard Schmidt, Commercial Director, France at Magnite. “Because Magnite’s buyer agent is embedded directly into the buying workflow, it can surface optimisation opportunities as they emerge and allows buyers to act on them faster to improve both operational efficiency and campaign performance. The results achieved with Amnet reinforce the value of connecting intelligence directly to execution, and we're excited to build on that momentum with more clients across EMEA.”

About Magnite
We’re Magnite (NASDAQ: MGNI), the world’s largest independent sell-side advertising company. Publishers use our technology to monetize their content across all screens and formats including CTV, online video, display, and audio. The world’s leading agencies and brands trust our platform to access brand-safe, high-quality ad inventory and execute billions of advertising transactions each month. Anchored in bustling New York City, sunny Los Angeles, mile high Denver, historic London, colorful Singapore, and down under in Sydney, Magnite has offices across North America, EMEA, LATAM, and APAC.

About Amnet
Founded in 2012, Amnet France is a leading programmatic trading desk helping more than 200 advertisers in France and internationally, helping brands address a wide range of digital marketing challenges, from brand building and performance marketing to drive-to-store strategies, audience creation and data-driven targeting. Amnet delivers programmatic campaigns across all major digital channels, including Display, Video, Social, Audio, Connected TV (CTV), and Digital Out-of-Home (DOOH).

Media Contact:
Eric Van Damme: [email protected]

Braze, Inc. (NASDAQ:BRZE) will release its second quarter earnings report after the closing bell on Tuesday, Sept. 8.

Analysts expect the New York-based company to report quarterly earnings of 16 cents per share, up from 15 cents per share in the year-ago period. The consensus estimate for BRZE’s quarterly revenue is $220.26 million. It reported $180.11 million last year, according to Benzinga Pro.

On May 27, Braze reported mixed first-quarter financial results.

Shares of Braze fell 3.9% to close at $31.96 on Friday.

Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.

Let’s have a look at how Benzinga’s most-accurate analysts have rated the company in the recent period.

DA Davidson analyst Clark Wright maintained a Buy rating and raised the price target from $33 to $40 on Sept. 2, 2026. This analyst has an accuracy rate of 73%. Barclays analyst Raimo Lenschow maintained an Overweight rating and boosted the price target from $31 to $38 on Sept. 2, 2026. This analyst has an accuracy rate of 72%. TD Cowen analyst Derrick Wood maintained a Buy rating and increased the price target from $30 to $36 on Aug. 27, 2026. This analyst has an accuracy rate of 72%. Oppenheimer analyst Brian Schwartz maintained an Outperform rating and boosted the price target from $30 to $36 on Aug. 27, 2026. This analyst has an accuracy rate of 59%. BTIG analyst Nick Altmann maintained a Buy rating and increased the price target from $30 to $35 on Aug. 14, 2026. This analyst has an accuracy rate of 68%. Trending

Considering buying BRZE stock? Here’s what analysts think:

Photo via Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.